Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Psoriatic Arthritis. Core disease mechanisms, molecular and cellular pathw...

This report is retrieval-only and is generated directly from Asta results.

• Papers retrieved: 19
• Snippets retrieved: 20

Relevant Papers

[1] Histopathology of Psoriatic Arthritis Synovium—A Narrative Review

• Authors: C. Tenazinha, R. Barros, J. Fonseca, E. Vieira-Sousa
• Year: 2022
• Venue: Frontiers in Medicine
• URL: https://www.semanticscholar.org/paper/253730e68e314db4b2d4cf81a495baedebf43669
• DOI: 10.3389/fmed.2022.860813
• PMID: 35847785
• PMCID: 9283901
• Citations: 16
• Influential citations: 1
• Summary: The psoriatic synovium shares general features of chronic inflammation with rheumatoid arthritis and other arthritis, such as hyperplasia of the intimal lining layer, sublining influx of inflammatory cells and neoangiogenesis, but recognizing disease-specific histopathologic findings may help in diagnosis and definition of therapeutic targets.
• Evidence snippets:
• Snippet 1 (score: 0.532) > Psoriatic arthritis (PsA) is a chronic inflammatory disease with high clinical heterogeneity that occurs the most commonly in patients with previously diagnosed psoriasis (Pso). It can involve joints, with heterogeneous patterns, and periarticular structures, such as the enthesis, tendon sheets, paratenons, but also the bone and the subcutaneous fat (1). Inflammation is considered to develop adjacent to bone insertions, affecting the enthesis and the synovium, and being associated with both processes of bone destruction and new bone formation. Clinical heterogeneity results from a wide range of severity and clinical features, that vary according to the tissues and body sites involved (2,3). Psoriatic arthritis pathogenesis is complex and detailed disease mechanisms are still unclear, with underlying polygenic and environmental predisposing factors. It is associated to type I major histocompatibility complex (MHC) alleles, with risk polymorphisms in genes related to interleukins (IL) 23 and 12, nuclear factor κB and tumor necrosis factor (TNF) that, when dysregulated, can promote the activation of inflammatory pathways (1). The study of psoriatic joint disease at the histopathology level has helped to understand disease mechanisms and may unravel new therapeutic targets and biomarkers, improving early diagnosis and treatment. > Available literature consists of either study reports or reviews of specific aspects, that often lack comparison to the most important synovitis counterpart of PsA, which is rheumatoid arthritis (RA). Herein we provide a descriptive and detailed description of the histopathologic findings concerning all levels of the synovial layer, aiming to identify what is known and what is yet to be understood, supporting physicians in biopsy interpretation and investigators in establishing questions.

[2] Molecular treatment trajectories within psoriatic T lymphocytes: a mini review

• Authors: Martyna Kuczyńska, M. Gabig-Cimińska, M. Moskot
• Year: 2023
• Venue: Frontiers in Immunology
• URL: https://www.semanticscholar.org/paper/e570bf86f327d17fe6f9b0c583ef3591f706928e
• DOI: 10.3389/fimmu.2023.1170273
• PMID: 37251381
• PMCID: 10213638
• Citations: 2
• Summary: Despite recent drug development having mainly centred on biological therapies for Ps, yet displaying serious limitations, SMDs acting on specific pathway factor isoforms or single effectors within T cell, could represent a valid innovation in real-world treatment patterns in patients with Ps.
• Evidence snippets:
• Snippet 1 (score: 0.499) > In Ps, both skin-associated cells and those recruited from the circulatory system, belonging to the acquired and innate immune systems, especially T lymphocytes (T cells), are involved in complex feedback mechanisms of the disease pathophysiology (8-13). The discovery that topical treatments for skin symptoms alter the T cells' phenotype has drawn a special attention to the molecular pathways modulated in immune cells under Ps (14). Except for the intracellular cross-talk, however, the interplay between the molecules involved in different signalling tracks (i.e. throughout calcium (Ca 2+ )/calcineurin (CaN)/nuclear factor of activated T-cell (NFAT), mitogen-activated protein kinase (MAPK)/c-Jun Nterminal kinase (JNK), phosphoinositide-3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR), Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathways) in T cells is of concern in the last few years, identifying them as potential targets in the management of Ps (7). At the same time, it became obvious that larger and further studies are desirable to fully explore signalling cascades involved in the pathogenesis of the disease, especially to accomplish knowledge gaps regarding pathological mechanisms within psoriatic T lymphocytes. The creation of Ps disease atlas showing a road map of intracellular molecular pathways and their regulation network supported by a library of therapeutic entities would be a highly respected and lucrative approach in the medical community as per our vision. A rather wide point of view must be mapped by connecting each piece of information, which consequently can help disease navigate and curing. Furthermore, the "new use of old medicine" would also refer to the development of new indications or new uses of drugs that were previously marketed for other purposes. Such innovative approach to research fits perfectly into the "me-too" strategy era (15), allowing to find the most appropriate molecule dedicated to the most effective disease regulation mode.
• Snippet 2 (score: 0.446) > Autoimmune diseases are reaching epidemic levels, in part, because there are so many of them. Current medicine lists between 80 and 100 different types of autoimmune disorders or diseases. Some of the more common ones include Psoriatic (Ps) disease, a non-communicable skin and/or joint condition, currently regarded as an immune-mediated inflammatory disease (IMID) (1)(2)(3)(4). Various molecular and cellular pathways are implicated in Ps development and progression, as well as in the pathogenic mechanisms associated with an inflammation in this hyperimmune condition. Our understanding of this complex network and its tight regulation, however, turns out to be still in its infancy. Such a situation, while frustrating, offers an opportunity for further progress in the development of therapies thanks to the potential increase in our knowledge that is taking place now. It actually allows us to refine the current treatment options as well as define novel ones, focused not only on stopping attacks in progress and managing symptoms of Ps, but also on targeting the roots of disease processes. This is trying to be accomplished by using therapeutic compounds, such as Small Molecule Drugs (SMDs), developed for innovative strategies targeting any portion of a molecule, regardless of the target's cellular location, in order to depress the immune system and reduce inflammation, alleviating other symptoms at the same time (5)(6)(7). Recent advances in understanding the pathogenesis of the Ps have already led to the development of a number of SMDs that have a low molecular weight, making them penetrate cells easily and affecting molecular pathways by targeting important cellular entities. They have advantages like oral routes of administration, decreasing healthcare costs and fewer immunological adverse events compared to biologics (6). Besides, we would like to point out the fact that SMDs can be developed not only from leads derived from rational drug design, but also isolated from natural resources, leading to the innovation of more desirable treatments with minimum side effects possible. > In Ps, both skin-associated cells and those recruited from the circulatory system, belonging to the acquired and innate immune systems, especially T lymphocytes (T cells), are involved in complex feedback mechanisms of the disease pathophysiology (8-13).

[3] Metabolic changes in psoriatic skin under topical corticosteroid treatment

• Authors: B. Sitter, M. Johnsson, J. Halgunset, T. Bathen
• Year: 2013
• Venue: BMC Dermatology
• URL: https://www.semanticscholar.org/paper/2fd048568eb68b2abc3d6bcca488188bb153d686
• DOI: 10.1186/1471-5945-13-8
• PMID: 23945194
• PMCID: 3751591
• Citations: 42
• Influential citations: 1
• Summary: It is demonstrated that metabolism in psoriatic skin becomes similar to that of un involved skin after effective corticosteroid treatment, and tissue levels are becoming more similar to metabolite levels in uninvolved skin.
• Evidence snippets:
• Snippet 1 (score: 0.484) > Psoriasis is a common immune-mediated disease that affects the skin and joints. The cause of the disease remains unknown. Many patients have a genetic predisposition. The disease affects around 2-3% of the population worldwide. Clinically, psoriatic plaques are characterized by sharply demarcated erythematous lesions with thick silvery scales, often distributed in a symmetrical pattern. Histopathologically there is hyperproliferation of epidermal cells and an inflammatory cell infiltrate [1]. There is increasing awareness that psoriasis is a multisystem affection with substantial comorbidity, particularly of cardiovascular diseases and metabolic syndrome [2]. The course is that of a chronic, relapsing disease which requires long term treatment. Various topical and systemic treatment options exist for psoriatic lesions. Topical corticosteroids remain the cornerstone, either used as monotherapy or in combination with other treatment modalities. These agents exert anti-inflammatory and immunosuppressive effects by stimulation or inhibition of the genes involved in inflammatory pathways, including inhibition of cytokine production and reduction of such mediators of inflammation as prostaglandins and leucotrienes, inhibition of T-cell proliferation and T-cell dependent immunity, and suppression of fibroblast and endothelial cell functions [3,4]. Corticosteroids also have anti-proliferative effects, by delaying the onset of DNA synthesis and decreasing the mitotic rate [5]. > Molecular studies of outbreak and healing of psoriatic lesions can provide insight in the underlying biological processes. Genome wide association scans (GWAS) have identified genetic susceptibility factors [6], and molecular analysis have revealed associations of psoriasis with specific molecular pathways [7,8]. Detailed molecular characterization of autoimmune diseases can provide information about mechanisms involved in disease progression and action of drugs, and also provide biomarkers to predict and monitor disease course. Cellular enzymatic processes involve small molecular metabolites as substrates, intermediates and end products, and such metabolites are crucial in energy turnover and membrane synthesis.

[4] Integration of Immunome With Disease-Gene Network Reveals Common Cellular Mechanisms Between IMIDs and Drug Repurposing Strategies

• Authors: Abhinandan Devaprasad, T. Radstake, A. Pandit
• Year: 2019
• Venue: Frontiers in Immunology
• URL: https://www.semanticscholar.org/paper/da3d168a672593e5da82bb4178e49118bc4b3170
• DOI: 10.3389/fimmu.2021.669400
• PMID: 34108969
• PMCID: 8181425
• Citations: 13
• Summary: The method identified top DACs, DAGs, common pathways, and proposed potential drug repurposing targets between IMIDs and built the DIME tool, paving way for future (pre-)clinical research.
• Evidence snippets:
• Snippet 1 (score: 0.482) > Objective Development and progression of immune-mediated inflammatory diseases (IMIDs) involve intricate dysregulation of the disease associated genes (DAGs) and their expressing immune cells. Due to the complex molecular mechanism, identifying the top disease associated cells (DACs) in IMIDs has been challenging. Here, we aim to identify the top DACs and DAGs to help understand the cellular mechanism involved in IMIDs and further explore therapeutic strategies. Method Using transcriptome profiles of 40 different immune cells, unsupervised machine learning, and disease-gene networks, we constructed the Disease-gene IMmune cell Expression (DIME) network, and identified top DACs and DAGs of 12 phenotypically different IMIDs. We compared the DIME networks of IMIDs to identify common pathways between them. We used the common pathways and publicly available drug-gene network to identify promising drug repurposing targets. Result We found CD4+Treg, CD4+Th1, and NK cells as top DACs in the inflammatory arthritis such as ankylosing spondylitis (AS), psoriatic arthritis, and rheumatoid arthritis (RA); neutrophils, granulocytes and BDCA1+CD14+ cells in systemic lupus erythematosus and systemic scleroderma; ILC2, CD4+Th1, CD4+Treg, and NK cells in the inflammatory bowel diseases (IBDs). We identified lymphoid cells (CD4+Th1, CD4+Treg, and NK) and their associated pathways to be important in HLA-B27 type diseases (psoriasis, AS, and IBDs) and in primary-joint-inflammation-based inflammatory arthritis (AS and RA). Based on the common cellular mechanisms, we identified lifitegrast as potential drug repurposing candidate for Crohn’s disease, and other IMIDs. Conclusion Our method identified top DACs, DAGs, common pathways, and proposed potential drug repurposing targets between IMIDs. To extend our method to other diseases, we built the DIME tool. Thus paving way for future (pre-)clinical research.

[5] The cardiometabolic conditions of psoriatic disease

• Authors: E. Toussirot, I. Gallais-Serezal, F. Aubin
• Year: 2022
• Venue: Frontiers in Immunology
• URL: https://www.semanticscholar.org/paper/3223edff0217b4cde6195064f6999082db825e2d
• DOI: 10.3389/fimmu.2022.970371
• PMID: 36159785
• PMCID: 9492868
• Citations: 29
• Summary: The available evidence on the epidemiology, clinical aspects and mechanisms of cardiometabolic conditions in patients with psoriasis and psoriatic arthritis are summarized.
• Evidence snippets:
• Snippet 1 (score: 0.477) > Psoriasis (PsO) and psoriatic arthritis (PsA), together known as psoriatic disease (PsD), are immune-mediated diseases with a chronic and relapsing course that affect the skin, the joints or both. The pathophysiology of PsO is complex and involves abnormal expression of keratinocytes and infiltration of the skin with dendritic cells, macrophages, neutrophils and T lymphocytes. Around 30% of patients with PsO develop arthritis with axial and/or peripheral manifestations. Both PsO and PsA share similar Th1- and Th17-driven inflammation, with increased production of inflammatory cytokines, including TNFα, IFN-γ, IL-17, IL-22, IL-23 in the skin and the synovial membrane. PsD is associated with a high burden of cardiometabolic diseases such as hypertension, diabetes, dyslipidemia, obesity, metabolic syndrome and cardiovascular (CV) complications as compared to the general population. These comorbidities share common immunopathogenic pathways linked to systemic inflammation, and are associated with the extent and severity of the disease. Morever, they can influence treatment outcomes in PsD. In this short review, we summarize the available evidence on the epidemiology, clinical aspects and mechanisms of cardiometabolic conditions in patients with PsD. We also discuss the impact of targeted treatments such as methotrexate and biological agents on these cardiometabolic conditions.

[6] Biological drugs targeting the immune response in the therapy of psoriasis

• Authors: S. Pastore, E. Gubinelli, L. Leoni, D. Raskovic, L. Korkina
• Year: 2008
• Venue: Biologics : Targets & Therapy
• URL: https://www.semanticscholar.org/paper/bdb05c19fa9b6a61c44172ac081f5af73d5e8ec5
• DOI: 10.2147/BTT.S2763
• PMID: 19707449
• PMCID: 2727880
• Citations: 20
• Summary: Recent findings on the molecular pathways relevant to the inflammatory response in psoriasis are overviewed and clinical experience with the drugs currently employed in the dermatologic manifestations, namely etanercept, infliximab, and efalizumab are presented.
• Evidence snippets:
• Snippet 1 (score: 0.464) > Chronic plaque psoriasis affects more than 2% of world population, has a chronic recurrent behavior, gives a heavy burden to the patients’ quality of life, and hence remains a huge medical and social problem. The clinical results of conventional therapies of psoriasis are not satisfactory. According to the current knowledge of the molecular and cellular basis of psoriasis, it is defined as an immune-mediated chronic inflammatory and hyperproliferative skin disease. A new generation of biological drugs, targeting molecules and cells involved into perturbed pro-inflammatory immune response in the psoriatic skin and joints, has been recently designed and applied clinically. These biological agents are bioengineered proteins such as chimeric and humanized antibodies and fusion proteins. In particular, they comprise the antitumor necrosis factor-α agents etanercept, infliximab, and adalimumab, with clinical efficacy in both moderate-severe psoriasis and psoriatic arthritis, and the anti-CD11a efalizumab with selective therapeutic action exclusively in the skin. Here, we overview recent findings on the molecular pathways relevant to the inflammatory response in psoriasis and present our clinical experience with the drugs currently employed in the dermatologic manifestations, namely etanercept, infliximab, and efalizumab. The growing body of clinical data on the efficacy and safety of antipsoriasis biological drugs is reviewed as well. Particular focus is given to long-term safety concerns and feasibility of combined therapeutic protocols to ameliorate clinical results.

[7] An Actual Insight into the Pathogenic Pathways of Ankylosing Spondylitis

• Authors: Emilia Păsăran, A. Diaconu, Corina Oancea, A. Bălănescu, S. Aurelian et al.
• Year: 2024
• Venue: Current Issues in Molecular Biology
• URL: https://www.semanticscholar.org/paper/a8625e59eee3e066a092d24e66e7a6e7a4ac6b9a
• DOI: 10.3390/cimb46110762
• PMID: 39590356
• PMCID: 11592934
• Citations: 8
• Summary: The current article aims to update and systematize the knowledge accumulated so far on this topic, focusing on the mechanisms that have been involved in the onset, progression, and severity of ankylosing spondylitis.
• Evidence snippets:
• Snippet 1 (score: 0.460) > Spondyloarthritis refers to a broad group of conditions that include ankylosing spondylitis, psoriatic arthritis, reactive arthritis, and enteropathic arthritis associated with Crohn’s disease or ulcerative colitis. They have been classified by the ASAS group (ASsessment in Ankylosing Spondylitis) into axial spondyloarthritis and peripheral spondyloarthritis. Common features include the absence of autoantibodies, genetic predisposition, and clinical aspects such as axial joint involvement, peripheral manifestations, and extra-articular involvement. However, the pathogenic mechanisms remain complex and incompletely elucidated, despite the fact that the specialized literature has described several pathways that act in synergy: genetic predisposition, environmental factors (infections and mechanical stress), or innate and acquired immune mechanisms. Finally, an inflammatory response is triggered by the recruitment of a large number of inflammatory cells and the release of innate cytokines in the affected areas: joints or periarticular or extraarticular tissues. The current article aims to update and systematize the knowledge accumulated so far on this topic, focusing on the mechanisms that have been involved in the onset, progression, and severity of ankylosing spondylitis.

[8] The Use of Biologic and Targeted Synthetic Disease-Modifying Drugs in the Treatment of Psoriatic Arthritis

• Authors: Rafal Ali, Arthur N. Lau, Lawrence H. Brent
• Year: 2024
• Venue: Biologics
• URL: https://www.semanticscholar.org/paper/9315c48bd3d2d7183484705e30ad6338a3a02d2b
• DOI: 10.3390/biologics5010001
• Summary: Various treatment options, focusing on biologic and targeted synthetic disease-modifying antirheumatic drugs, are discussed, targeting different inflammatory pathways in psoriatic arthritis.
• Evidence snippets:
• Snippet 1 (score: 0.456) > Psoriatic arthritis is a complex, systemic inflammatory condition that has similarities with both psoriasis and other inflammatory joint diseases, such as rheumatoid arthritis and spondyloarthritis. Although the precise mechanisms of PsA are not known, it is thought to result from a combination of genetic predisposition and environmental triggers that lead to inflammatory processes within both the skin and joints [25][26][27] (Figure 7). Despite these shared pathways, the specific immune mechanisms and clinical manifestations can vary significantly between the skin and joint disease. > IL-23 signaling pathways (IL-23R), which play significant roles in the inflammatory process characteristic of PsA and PsO [31]. > Environmental factors also play a role in the development of PsA, especially in individuals with psoriasis. Potential triggers include infections like streptococcal infection, as well as trauma and obesity. [32,33]. Furthermore, changes in the gut and skin microbiomes might contribute to disease pathogenesis [34,35], although it is not clear whether these changes are causal or correlative. Dysbiosis in the gut may trigger IL-23 production [36]. IL-23 is produced by resident CD14+ myeloid cells in the enthesis [37], which activates resident CD4-, CD8-, and IL-23R+ T cells [38]. The relationship between environmental factors and genetic predisposition underscores the multifactorial nature of PsA. > The immune responses in PsA are driven by a dysregulation of both innate and adaptive immunity [39]. Key players include T cells, particularly CD8+ T cells, and monocytes, which contribute to inflammation in the skin and joints [40,41]. Cytokine pathways, especially those involving TNF-α, IL-23/IL-17, and IL-22 [36,42], play crucial roles in the pathogenesis of PsA, as these cytokines are found at elevated levels in affected tissues. The overlap of immune pathways in PsA and psoriasis supports the idea of shared pathogenetic origins, although the distinct clinical manifestations in skin and joint disease indicate unique underlying mechanisms in each [36,43,44].

[9] Proprotein Convertase Subtilisin/Kexin Type 9, Angiopoietin-Like Protein 8, Sortilin, and Cholesteryl Ester Transfer Protein—Friends of Foes for Psoriatic Patients at the Risk of Developing Cardiometabolic Syndrome?

• Authors: J. Krahel, A. Baran, T. Kamiński, I. Flisiak
• Year: 2020
• Venue: International Journal of Molecular Sciences
• URL: https://www.semanticscholar.org/paper/29ef0ba870ea75d9f92d8c3bcfd919ccf3548724
• DOI: 10.3390/ijms21103682
• PMID: 32456228
• PMCID: 7279158
• Citations: 18
• Influential citations: 1
• Summary: The role of four proteins: proprotein convertase subtilisin/kexin type-9 (PSCK9), angiopoietin-like protein 8 (ANGPLT8), sortilin (SORT1), and cholesteryl ester transfer proteins (CEPT) as plausible links between psoriasis and CMS are discussed.
• Evidence snippets:
• Snippet 1 (score: 0.454) > Psoriasis is a common, disfiguring, and stigmatizing immune-metabolic skin disease affecting approximately 2-4% of the world population [1,2]. In history, psoriasis was considered as a solely dermatological condition altering the skin, nails, and joints with unexplained pathophysiology. Since 2000, there has been a rapid rise in the pairing of psoriasis with the immune system and metabolic syndrome, which has led scientists to identify psoriasis as an immune-metabolic disease. Psoriatic patients tend to develop metabolic syndrome (MetS), including abdominal obesity, cardiometabolic diseases (CMDs), diabetes mellitus (DM), dyslipidemia, and non-alcoholic fatty liver disease (NALFD) [3]. Today, many factors lead to the occurrence and progression of the disease, namely, genetic predisposition, lifestyle, viral and bacterial infections, and numerous medications used in cardiology and immunology [1,4]. The exact etiology and molecular background of psoriasis have not been dealt with in-depth, but recent years have produced abundant new clinical findings that clarified part of psoriasis pathophysiology. > First, the innate and adaptive immune responses and cytokines-dependent mechanisms are considered fundamental pathological processes priming the occurrence and severity of the disease. Inflammation is the immune system's response to harmful stimuli, such as pathogens, damaged cells, toxic compounds, or irradiation. In general, a lasting, pro-inflammatory state is found in various conditions, including atherosclerosis, obesity, and psoriasis [1]. Acute and chronic phases of inflammatory process have been linked to increased morbidity of cardiovascular disease, neurological disorders, different types of cancer, and higher risk of deaths from these conditions. Interestingly, studying the plethora of different molecular and genomic pathways related to inflammatory processes resulted in the identification of pathways that are common for both, psoriasis and CMS.

[10] Ex vivo cytokine production in psoriatic disease: Towards specific signatures in cutaneous psoriasis and peripheral psoriatic arthritis

• Authors: G. Larid, A. Delwail, Thomas Dalle, Philippe Vasseur, C. Silvain et al.
• Year: 2022
• Venue: Frontiers in Immunology
• URL: https://www.semanticscholar.org/paper/b655abb93d1539aec706f058d00d2ecc23d4d69a
• DOI: 10.3389/fimmu.2022.993363
• PMID: 36426370
• PMCID: 9678922
• Citations: 7
• Summary: PsO and the different PsA subtypes exhibit distinct ex vivo cytokine production profiles and common features of the so-called PsD, and the crucial role of immune cell interactions with different patterns of interaction depending on clinical phenotype is highlighted.
• Evidence snippets:
• Snippet 1 (score: 0.451) > Psoriasis is an inflammatory cutaneous disorder with prevalence up to 3% of people in industrialized countries (1). Originally described as a skin and/or articular pathology, psoriasis appears as a disease involving other tissue damage. In the last ten years, the concept of "psoriatic disease" (PsD) has emerged, which encompasses all the clinical aspects of so-called cutaneous psoriasis (PsO), psoriatic arthritis (PsA), and associated comorbidities such as cardio-metabolic disorders (2)(3)(4)(5). As PsD is a systemic disease, patients can present features of PsO, PsA, or both. Numerous studies focusing on PsO patients do not indicate if patients have articular involvement or not. Likewise, among PsO patients, many patients suffering from PsA are undiagnosed (6). This common vagueness in population's description creates a potential bias both for the clinical diagnosis which determines the follow-up and treatment of patients, and for studies describing the physiopathological mechanisms of PsD, in which the two clinical entities may not be clearly differentiated from one to another. > PsD is a polygenic inflammatory disorder of which the pathophysiology raises numerous questions (7,8). Interestingly, among the multiple polymorphisms associated with PsO or PsA, a significant number involves genes encoding for cytokines such as IL-12B, IL-23A, IL-23R, IL-13, IL-36G, IL-20, TNFAIP3 or TNFIP1 (7)(8)(9), leading to investigations of cytokine profiles in PsO or PsA in order to determine specific cytokine signatures. To date, different biological approaches have been applied to PsD, including serum analysis, transcriptomic analysis, and ex vivo studies, but the majority of these studies do not discriminate between the two clinical entities. While transcriptomic approaches from inflamed skin or synovial tissue samples provide relevant information on the pathophysiology of both diseases, their use in routine practice is not possible for diagnosis, insofar it requires invasive techniques to obtain samples.

[11] Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?

• Authors: L. Coates, O. FitzGerald, P. Helliwell, C. Paul
• Year: 2016
• Venue: Seminars in arthritis and rheumatism
• URL: https://www.semanticscholar.org/paper/3cc18d8ab18be64eb75c28ea6be79c285f017bec
• DOI: 10.1016/j.semarthrit.2016.05.012
• PMID: 27388027
• Citations: 154
• Influential citations: 4
• Summary: Increased understanding of the immunopathogenesis allowed development of targeted treatments; however, despite a variety of potentially predictive genetic, protein and cellular biomarkers, there is still significant unmet need in these three inflammatory disorders.
• Evidence snippets:
• Snippet 1 (score: 0.448) > OBJECTIVES > To review the pathophysiology, co-morbidities, and therapeutic options for psoriasis, psoriatic arthritis and rheumatoid arthritis in order to further understand the similarities and differences in treatment paradigms in the management of each disease. New targets for individualized therapeutic decisions are also identified with the aim of improving therapeutic outcome and reducing toxicity. > SEARCH STRATEGY > Using the PubMed database, we searched literature published from 2000 to 2015 using combinations of the key words "psoriasis," "psoriatic arthritis," "rheumatoid arthritis," "pathogenesis," "immunomodulation," and "treatment." > INCLUSION AND EXCLUSION CRITERIA > This was a non-systematic review and there were no formal inclusion and exclusion criteria. > DATA EXTRACTION > Abstracts identified in the search were screened for relevance and articles considered appropriate evaluated further. References within these selected articles were also screened. Information was extracted from 198 articles for inclusion in this report. > DATA SYNTHESIS > There was no formal data synthesis. Articles were reviewed and summarized according to disease area (psoriasis, psoriatic arthritis, and rheumatoid arthritis). > HEADLINE RESULTS > The pathophysiology of psoriasis, psoriatic arthritis, and rheumatoid arthritis involves chronic inflammation mediated by pro-inflammatory cytokines. Dysfunction in integrated signaling pathways affecting different constituents of the immune system result in varying clinical features in the three diseases. Co-morbidities, including cardiovascular disease, malignancies, and non-alcoholic fatty liver disease are increased. Increased understanding of the immunopathogenesis allowed development of targeted treatments; however, despite a variety of potentially predictive genetic, protein and cellular biomarkers, there is still significant unmet need in these three inflammatory disorders.

[12] State of the Art Review on the Treatment of Psoriatic Disease

• Authors: E. Pelechas, E. Kaltsonoudis, Michalis P. Migkos, N. Koletsos, P. Karagianni et al.
• Year: 2024
• Venue: Mediterranean Journal of Rheumatology
• URL: https://www.semanticscholar.org/paper/0dc58150e9ccdb1ff88f0971378f3cc7ca6e45df
• DOI: 10.31138/mjr.040123.sot
• PMID: 38736956
• PMCID: 11082764
• Citations: 2
• Summary: This review aims to highlight the newest treatments for psoriatic disease, which are expected to significantly reduce unmet needs and treatment gaps.
• Evidence snippets:
• Snippet 1 (score: 0.448) > Psoriasis is a chronic inflammatory disease that is characterised by skin lesions which in some cases are accompanied by systemic manifestations.Due to its high heterogeneity, the World Health Organisation (WHO) has classified psoriasis as a serious disease. 1 It affects 2-3% of the population and presents significant effects on the physical and mental health of the patients. 2,3Psoriatic lesions result from an increased proliferation and disturbed differentiation of the keratinocytes. 4In the majority of cases, skin lesions precede joint manifestations as well as other organ infestations (bowel, eyes).Given the aforementioned various clinical manifestations, the term psoriatic disease probably reflects in a better manner the whole clinical picture of those affected. 5In addition, psoriatic disease may develop a variety of well-known associated comorbidities including cardiovascular disease, obesity and metabolic syndrome, diabetes, osteoporosis, malignancy, fatty liver disease, depression, and anxiety. 6arious immune-mediated cellular pathways such as that of TNF-α, IL-23, and IL-17 are involved in the pathophysiology of psoriasis and psoriatic arthritis, and their understanding has led to remarkably better control of it. 4,7owadays, there are various treatment options that are already approved by the regulatory bodies and rely on blocking those cytokines with good to excellent results so far.The main aim of the so-called targeted treatments with biologics is the long-term modulation of the psoriatic disease, with immediate but also long-term results of the signs and symptoms of the disease including the radiological progression.Finally, there is a growing body of evidence that not only the psoriatic disease in sine gets

[13] Molecular profiling of clinical remission in psoriatic arthritis reveals dysregulation of FOS and CCDC50 genes: a gene expression study

• Authors: M. M. Angioni, A. Floris, Ignazio Cangemi, M. Congia, E. Chessa et al.
• Year: 2023
• Venue: Frontiers in Immunology
• URL: https://www.semanticscholar.org/paper/543e695473c5930c2897fc60a5e3751548479d61
• DOI: 10.3389/fimmu.2023.1274539
• PMID: 37965313
• PMCID: 10641465
• Citations: 4
• Influential citations: 1
• Summary: The transcriptomic profile of clinical remission in PsA is similar to a healthy condition, but not identical, differing for the expression of FOS and CCDC50 genes, which appears to play a key role in its achievement.
• Evidence snippets:
• Snippet 1 (score: 0.446) > Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by wide clinical heterogeneity due to the variable combination of six major domains, namely, skin and nail psoriatic lesions, peripheral arthritis, axial disease, dactylitis, and enthesitis (1). It is recognized as a potentially disabling disease, as late and inadequate control of disease activity may result in structural damage and disability (2). > According to the European Alliance of Associations for Rheumatology (EULAR) and the Group for Research in Psoriasis and PsA (GRAPPA) recommendations, treatment of PsA should aim primarily at reaching the target of remission by regular disease activity assessment and appropriate adjustment of therapy (3,4). Although this approach represents one of the strongest and most widely shared recommendations, there are still relevant issues regarding its application in clinical practice. In particular, the definition of remission is still open to discussion among experts and represents a significant challenge in the management of PsA (5). Several definitions of clinical remission, based on composite indices combining objective (e.g., tender and swollen joint count or enthesitis and dactylitis count (6)) and subjective (e.g., scales for pain or general health) measurements of disease activity are currently used in clinical practice and trials (7). However, the clinical heterogeneity of PsA, the potential persistence of subclinical disease activity demonstrated in ultrasonography studies, and the possible progression of structural damage in patients classified as in clinical remission (8), highlight the urgent need for a sensitive and specific biomarker supporting the accurate identification of remission. > Several genetic, circulating, and tissue factors have been studied as biomarkers in the management of different aspects of PsA, including diagnosis and assessment or prediction of disease activity, severity, and response to treatment (9)(10)(11)(12)(13). However, none of these has been extensively validated and then translated into routine clinical practice (10,14). In particular, despite remission being recommended as the primary goal in PsA treatment, to our knowledge, no studies have been specifically designed to identify the underlying molecular mechanisms and potential biomarkers.

[14] Psoriatic Synovitis: Singularity and Potential Clinical Implications

• Authors: R. Celis, A. Cuervo, J. Ramírez, J. Cañete
• Year: 2019
• Venue: Frontiers in Medicine
• URL: https://www.semanticscholar.org/paper/1536df6b7385be85f1920e72ff6d8e69cc835206
• DOI: 10.3389/fmed.2019.00014
• PMID: 30805340
• PMCID: 6378889
• Citations: 37
• Influential citations: 2
• Summary: Modern methodologies, as MALDI-Mass Spectrometry Imaging, applied to the study of synovial tissue have revealed metabolic and lipid signatures which could support clinical decision-making in the diagnosis of PsA and RA and to go further toward the personalized medicine.
• Evidence snippets:
• Snippet 1 (score: 0.444) > Psoriatic arthritis (PsA) is an immuno-inflammatory disease with a heterogeneous clinical presentation as affects musculoskeletal tissues (arthritis, enthesitis, spondylitis), skin (psoriasis) and, less frequently, eye (uveitis) and bowel (inflammatory bowel disease). It has been suggested that distinct affected tissues could exhibit different immune-inflammatory pathways so complicating the understanding of the physiopathology of psoriatic disease as well as its treatment. Despite of the key pathogenic and clinical relevance that enthesitis has in PsA, peripheral arthritis is more easily perceived. At the macroscopic level, PsA synovitis has predominantly tortuous, bushy vessels, whereas rheumatoid arthritis (RA) is characterized by mainly straight, branching vessels so reflecting prominent neo-angiogenesis in PsA. Synovial biopsies have demonstrated a similar cellular and molecular picture in PsA and RA, although some differences have been reported at the group level, as higher density of vessels, CD163+ macrophages, neutrophils and mast cells in PsA. In fact, synovial IL-17+ mast cells are significantly increased in PsA and produce more IL-17A compared with RA, and a proof of concept study supports its relevant role in the synovitis of SpA, included PsA. As firstly reported in RA, synovial lymphoid neogenesis is found also in the same proportion of PsA as in RA patients, despite the lack of autoantibodies in PsA. These lymphoid structures are associated with activation of the IL-23/Th17 pathway in RA and seemly in PsA, which could be useful to stratify RA patients. Immunohistochemical and transcriptomic methodologies have still not found synovial biomarkers useful to distinguish psoriatic from rheumatoid synovitis at the patient level. However, modern methodologies, as MALDI-Mass Spectrometry Imaging, applied to the study of synovial tissue have revealed metabolic and lipid signatures which could support clinical decision-making in the diagnosis of PsA and RA and to go further toward the personalized medicine.

[15] Proteomics in Psoriasis

• Authors: L. Chularojanamontri, Norramon Charoenpipatsin, N. Silpa‐archa, C. Wongpraparut, V. Thongboonkerd
• Year: 2019
• Venue: International Journal of Molecular Sciences
• URL: https://www.semanticscholar.org/paper/d2a4ace792f0c9cc650f5741e47dbaff5690738a
• DOI: 10.3390/ijms20051141
• PMID: 30845706
• PMCID: 6429319
• Citations: 26
• Summary: This review summarizes and discusses all of the previous studies that applied various modalities of proteomics technologies to psoriatic skin disease and leads to novel mechanisms and new hypotheses of the disease pathogenesis.
• Evidence snippets:
• Snippet 1 (score: 0.443) > Psoriasis is a common, chronic, immune-mediated, inflammatory skin disease affecting humans worldwide with increasing prevalence and incidence, depending on geographical area [1]. The most common form is chronic plaque psoriasis, which is characterized by well-demarcated, erythematous plaques with silvery scales, accounting for approximately 85% of all psoriatic patients [2]. Although chronic plaque psoriasis can be found on all parts of the body, the most commonly affected areas include the elbows, knees, and scalp [3]. Psoriasis has been thought to be driven primarily by innate and adaptive immune systems that can be modified by genetic and environmental factors (e.g., alcohol, drugs, infections, skin trauma, smoking, and stress). The inflammatory cascade involves not only the skin but also other organs, leading to several comorbidities, e.g., psoriatic arthritis, metabolic syndrome (diabetes mellitus, hypertension, dyslipidemia, obesity, etc.), cardiovascular disease, non-alcoholic fatty liver disease, and kidney disorders [4]. Several lines of evidence have shown that T-cells, especially Th1 and Th17 cells, play crucial roles in such inflammatory responses [5]. However, antigen-antibody interactions also play important role, as demonstrated by the deposition of immunoglobulin G (IgG) and complement components in the upper epidermis of psoriatic skin [6]. Even with the aforementioned knowledge and advancements, the pathogenesis of psoriasis remains to be elucidated as there is a major part below the tip of the iceberg that is still covered, leading to unmet clinical needs [7]. In addition, current clinical practice in psoriasis for diagnostics, prognostics, and determination of the therapeutic outcome relies mainly on clinical findings and routine laboratory tests that frequently involve invasive procedures (i.e., skin and tissue biopsies) [7,8]. These limitations therefore warrant further investigations to better understand psoriatic pathogenesis and disease mechanisms, to define novel biomarkers for earlier and better diagnostics/prognostics, and to monitor treatment efficacy and drug-induced toxicities.

[16] Role of Recombinant Proteins for Treating Rheumatoid Arthritis

• Authors: Mahboubeh Soleimani Sasani, Y. Moradi
• Year: 2024
• Venue: Avicenna Journal of Medical Biotechnology
• URL: https://www.semanticscholar.org/paper/455e132608b909e67ea29486bb151fb6d4a3ef6c
• DOI: 10.18502/ajmb.v16i3.15739
• PMID: 39132628
• PMCID: 11316508
• Citations: 1
• Summary: The genetic and immunological factors that influence the development of RA, recombinant proteins, methods of using these proteins, approved drugs, and side effects associated with treating RA are discussed.
• Evidence snippets:
• Snippet 1 (score: 0.441) > Rheumatoid Arthritis (RA) is a chronic inflammatory disease that affects synovial joints and leads to pain, stiffness, and reduced mobility. Although the exact cause of this disease is not fully known, it appears to be an autoimmune disease in which the immune system mistakenly attacks the body's tissues. This problem is the result of a combination of genetic factors, the environment, and the immune system. RA is a complex disease involving both resident cells and infiltrating cells in membrane tissue 1 . In this disease, significant amounts of new vessels are formed in the membrane tissue, facilitating invasion by lymphocytes and monocytes and transforming a cell-free, loose cavity membrane into an abnormal, tumor-like invasive tissue. Micro vessels proliferate, forming straight vessels and branching regularly 1 . Studies have shown that the synovial fluid in patients with RA is highly inflamed in all joints and expresses much inflammatory genes 2 . The pathophysiology of RA is heterogeneous and includes defects in the innate and adaptive immune systems, genetic and environmental factors, autoantibodies, cellular changes, signaling pathways, and metabolism 1 . Understanding the role of individual variations in the cellular and molecular mechanisms associated with RA will significantly improve clinical care and patient outcomes. Individualized responses to standard therapy are observed in RA because of pathophysiological heterogeneity, ultimately leading to poor overall prognosis 2 . Key cellular and molecular findings in RA include angiogenesis, B cells, fibroblasts, reduced oxygen levels, synovial tissue, and T cells. Researchers are investigating altered metabolic pathways underlying synovial inflammation in RA 1 . The molecular and cellular heterogeneity of RA is a hot topic, and understanding the underlying mechanisms may lead to therapeutic intervention 3 . RA is currently treated worldwide to reduce inflammation, relieve pain, and slow the progression of joint damage. Conventional treatments include nonsteroidal anti-inflammatory drugs, diseasemodifying antirheumatic drugs, and biological agents, and in recent years, recombinant proteins have emerged as promising biological agents that can target specific proteins or cells involved in the inflammatory response 4 . Recombinant proteins are synthetic proteins that are produced in the laboratory using genetic engineering techniques.

[17] Case Report: Severe thrombocytopenia induced by adalimumab in rheumatoid arthritis: A case report and literature review

• Authors: T. Liao, Mengqing Li, Tian Yuan, Qifu Hong, Yu Zeng et al.
• Year: 2022
• Venue: Frontiers in Pharmacology
• URL: https://www.semanticscholar.org/paper/a544c421bc5d4e5b6c2672df1216d7b444304e2b
• DOI: 10.3389/fphar.2022.1041884
• PMID: 36386149
• PMCID: 9640920
• Citations: 5
• Influential citations: 1
• Summary: It is suggested immunoglobulins could be considered for the treatment of refractory thrombocytopenia in a patient with RA who was treated with adalimumab.
• Evidence snippets:
• Snippet 1 (score: 0.435) > Rheumatoid arthritis is a chronic systemic autoimmune illness that can cause joint discomfort, swelling and deformity. It is characterized by chronic synovial inflammatory reaction. The main pathological manifestations include synovial lining cell proliferation, interstitial inflammatory cell infiltration, microvascular neogenesis, pannus formation and cartilage and bone tissue destruction. It seriously affects the quality of life of the patients and multiple systems of the body. There are many molecular mechanisms in rheumatoid arthritis, such as the IL31/ IL33 axis, which leads to gene and protein activation of inflammatory diseases through cascade reactions (Murdaca et al., 2019). Subsequently involved in the secretion of TNF-α. Tumor necrosis factor is one of the major inflammatory cytokines in the RA patients. It regulates the production of inflammatory factor like IL-6, IL-8, MCP-1, and VEGF, as well as the recruitment of immune and inflammatory cells to the affected joint (Lim et al., 2018). Therefore, it plays an important role in the pathological development of RA. As a therapeutic target in rheumatoid arthritis, anti-TNF-α drugs have been used in the RA patients since mid-1990s. Numerous clinical studies have demonstrated that anti-TNF-α drugs can improve not only the clinical signs and symptoms of RA patients, but also their joint function and imaging results (Caporali et al., 2018). Anti-TNFα drugs were effective and were well tolerated by many RA patients. Multiple recommendations advocate the clinical use of anti-TNF-α drugs. 2021 American College of Rheumatology Guidelines recommend that patients who do not respond adequately to methotrexate monotherapy be considered for the addition of anti-TNF-α drugs (Fraenkel et al., 2021). In addition to RA, anti-TNF-α drugs are also used in the treatment of multiple autoimmune diseases, such as Crohn's disease, ulcerative colitis, psoriatic arthritis, etc. (Lim et al., 2018).

[18] Gene Profiling of a 3D Psoriatic Skin Model Enriched in T Cells: Downregulation of PTPRM Promotes Keratinocyte Proliferation through Excessive ERK1/2 Signaling

• Authors: G. Rioux, F. Turgeon, G. Le-Bel, Camille Grenier, S. Guérin et al.
• Year: 2022
• Venue: Cells
• URL: https://www.semanticscholar.org/paper/82bd7be1ba7527e36144a47f25d9e4b840b01b73
• DOI: 10.3390/cells11182904
• PMID: 36139479
• PMCID: 9497242
• Citations: 14
• Summary: A tissue-engineered, two-layered human psoriatic skin substitute enriched in T cells may prove particularly useful in deciphering the mechanistic details of psoriasis pathogenesis and provide a relevant biomaterial for the study of potential therapeutic targets.
• Evidence snippets:
• Snippet 1 (score: 0.435) > Psoriasis is a complex, immune-mediated skin disease involving a wide range of epithelial and immune cells. The underlying mechanisms that govern the epidermal defects and immunological dysfunction observed in this condition remain largely unknown. In recent years, the emergence of new, more sophisticated models has allowed the evolution of our knowledge of the pathogenesis of psoriasis. The development of psoriatic skin biomaterials that more closely mimic native psoriatic skin provides advanced preclinical models that will prove relevant in predicting clinical outcomes. In this study, we used a tissue-engineered, two-layered (dermis and epidermis) human skin substitute enriched in T cells as a biomaterial to study both the cellular and molecular mechanisms involved in psoriasis’ pathogenesis. Gene profiling on microarrays revealed significant changes in the profile of genes expressed by the psoriatic skin substitutes compared with the healthy ones. Two genes, namely, PTPRM and NELL2, whose products influence the ERK1/2 signaling pathway have been identified as being deregulated in psoriatic substitutes. Deregulation of these genes supports excessive activation of the ERK1/2 pathway in psoriatic skin substitutes. Most importantly, electrophoresis mobility shift assays provided evidence that the DNA-binding properties of two downstream nuclear targets of ERK1/2, both the NF-κB and Sp1 transcription factors, are increased under psoriatic conditions. Moreover, the results obtained with the inhibition of RSK, a downstream effector of ERK1/2, supported the therapeutic potential of inhibiting this signaling pathway for psoriasis treatment. In conclusion, this two-layered human psoriatic skin substitute enriched in T cells may prove particularly useful in deciphering the mechanistic details of psoriatic pathogenesis and provide a relevant biomaterial for the study of potential therapeutic targets.

[19] Proteomic and Metabolomic Changes in Psoriasis Preclinical and Clinical Aspects

• Authors: A. Radulska, I. Pelikant-Małecka, Kamila Jendernalik, I. Dobrucki, L. Kalinowski
• Year: 2023
• Venue: International Journal of Molecular Sciences
• URL: https://www.semanticscholar.org/paper/5d8553859955e0601b9f6259f05c75467ddce0c2
• DOI: 10.3390/ijms24119507
• PMID: 37298466
• PMCID: 10253645
• Citations: 12
• Summary: Proteomics and metabolomics strategies and their utility in research and clinical practice in psoriasis and psoriatic arthritis are discussed and their contribution to the discovery of biomarkers and targets for biological drugs is highlighted.
• Evidence snippets:
• Snippet 1 (score: 0.434) > In the study 'Identification of New Prognostic Markers in Psoriatic Arthritis', the concentration of IL 17A and other cytokines was correlated with markers of bone remodeling, identifying the molecular pathways involved in psoriatic arthropathy. The progression of psoriasis leads to the development of many comorbidities other than psoriatic arthritis, such as metabolic syndrome and cardiovascular diseases [122]. The study 'Psoriasis Inflammation and Systemic Co Morbidities' was intended to explore the pathophysiology of psoriasis and its comorbidities, but it also provided guidance on how long-term treatment of inflammation can reduce or prevent cardiovascular events. > The next five selected clinical trials presented in Table 3 are currently recruiting patients for candidate biomarkers investigation to predict severity and responsiveness to treatment in psoriasis and psoriatic arthritis. These open-label trials are multicentered, and a large number of patients are planned to be enrolled. The smallest estimated number of participants is 50 patients in the 'An Explorative Psoriasis Biomarker Study', conducted in the Netherlands. The clinical trial requires fewer participants than others currently recruiting. However, it assumes a very wide breadth of its outcome. The study involves the analysis of various chemokines, cytokines, and immune cells in the blood and lesion and non-lesion skin, determination of skin and fecal microbiome, analysis of epidermal homeostasis and immune cell infiltration, measurement of skin surface biomarkers concentration and stratum lipidomic analysis of corneum and biopsy transcriptome.

Notes

• This provider combines search_papers_by_relevance with snippet_search.
• No synthesis or second-stage model call is performed.

Disorder

• Name: Psoriatic Arthritis
• Category: Complex
• Existing deep-research providers: falcon, perplexity
• Existing evidence reference count in YAML: 30

Key Pathophysiology Nodes

• Immune-Mediated Inflammatory Arthritis
• Cytokine Pathway Activation
• Enthesitis as a Primary Event
• Deep research literature mapping

Citation Inventory (for evidence mapping)

• DOI:10.1002/art.11331
• DOI:10.1002/art.43286
• DOI:10.1007/s11926-024-01144-x
• DOI:10.1101/2025.08.26.25334362
• DOI:10.1101/2025.08.26.25334362|
• DOI:10.1111/exd.12572
• DOI:10.1111/exd.15151
• DOI:10.1126/sciimmunol.adu0284
• DOI:10.1155/2019/1824624
• DOI:10.3389/fimmu.2023.1081256
• DOI:10.3389/fimmu.2023.1100869
• DOI:10.3389/fmed.2019.00014
• DOI:10.3389/fphar.2021.672515
• DOI:10.3390/nu17081323
• DOI:10.3390/nu17081323|
• DOI:10.3899/jrheum.2024-0593
• DOI:10.3899/jrheum.2024-0593|
• DOI:10.3899/jrheum.2025-0273
• DOI:10.46497/archrheumatol.2025.10934
• PMID:14613270
• PMID:2095178
• PMID:21549221
• PMID:22133017
• PMID:32159793
• PMID:40528683

Disease Pathophysiology Research Report

Target Disease - Disease Name: Psoriatic Arthritis (PsA) - Category: Complex

Pathophysiology description (narrative synthesis) Psoriatic arthritis is an immune‑mediated inflammatory disease in which enthesis‑resident and synovial immune–stromal circuits converge, driven principally by the IL‑23/IL‑17 axis and amplified by TNF and other cytokines, producing synovitis, enthesitis, dactylitis, osteitis, and a paradoxical combination of bone erosion and new bone formation. Contemporary models emphasize the synovio‑entheseal complex: mechanical microdamage at entheses triggers innate and innate‑like lymphoid responses that can spill into adjacent synovium and nail–DIP units; imaging and anatomical studies support enthesitis as a primary lesion that may predate clinical arthritis and explain nail–DIP co‑localization. Therapeutically validated pathways (IL‑17/IL‑23, TNF, and JAK/TYK2) mirror these mechanisms. Genetic susceptibility implicates HLA class I and antigen processing/presentation (HLA‑B27, ERAP1/2) alongside IL‑23/Th17 and interferon/JAK signaling genes (IL23R, IL12B, TYK2, TRAF3IP2), aligning with observed cell‑type programs (Th17/Tc17, γδ T cells, MAIT, ILC3, dendritic cells including pDCs) and tissue remodeling pathways (RANKL‑osteoclastogenesis; Wnt inhibitors DKK1/SOST shaping new bone). (mcgonagle2024grappa2023debate pages 1-2, dilek2025immuneresponseand pages 1-2, raychaudhuri2024jakstatsignalingand pages 1-3, allardchamard2025exploringthegenetic pages 7-9, dilek2025immuneresponseand pages 10-11)

Direct quotes supporting key concepts - “The enthesitis hypothesis posits that enthesitis is a primary lesion and that inflammation at the enthesis initiates the musculoskeletal symptoms of psoriatic arthritis (PsA) and spondyloarthropathies (SpA).” URL/Date: The Journal of Rheumatology, Aug 2024, doi:10.3899/jrheum.2024-0593 (mcgonagle2024grappa2023debate pages 1-2) - JAK/STAT is emphasized as “a key regulatory role” for cytokines relevant to SpA pathogenesis with therapeutic implications for JAK/TYK2 inhibition. URL/Date: Current Rheumatology Reports, Mar 2024, doi:10.1007/s11926-024-01144-x (raychaudhuri2024jakstatsignalingand pages 1-3)

1) Core pathophysiology - Primary mechanisms: Enthesis‑driven inflammation within the synovio‑entheseal complex; cytokine circuits dominated by IL‑23→STAT3/TYK2/JAK2 signaling sustaining Th17/innate‑like IL‑17 production; IL‑17/TNF acting on stromal cells to induce chemokines/MMPs and maintain synovitis; bone pathways coupling inflammation to osteoclastogenesis (RANKL) and osteoproliferation (Wnt/DKK1/SOST axis). (mcgonagle2024grappa2023debate pages 1-2, raychaudhuri2024jakstatsignalingand pages 1-3, dilek2025immuneresponseand pages 1-2, dilek2025immuneresponseand pages 10-11) - Dysregulated molecular pathways: IL‑23/IL‑17 and TNF signaling; JAK/STAT (notably TYK2/JAK2 with IL‑23); interferon/type I IFN networks (pDC‑linked); Wnt antagonism via DKK1/SOST; RANK–RANKL–OPG axis. (raychaudhuri2024jakstatsignalingand pages 1-3, dilek2025immuneresponseand pages 1-2, dilek2025immuneresponseand pages 10-11) - Affected cellular processes: Cytokine receptor signaling; NF‑κB activation; matrix remodeling (MMP induction); osteoclast differentiation and osteoblast/Wnt regulation; antigen processing/presentation (HLA class I–ERAP). (raychaudhuri2024jakstatsignalingand pages 1-3, dilek2025immuneresponseand pages 1-2, allardchamard2025exploringthegenetic pages 7-9)

2) Key molecular players - Genes/Proteins (HGNC): HLA‑B27; ERAP1/ERAP2; IL23R; IL12B; TYK2; TRAF3IP2 (Act1); DKK1; RANKL/TNFSF11; SOST. Evidence: recent genetics aggregations and mechanistic reviews place IL‑23/Th17 and antigen‑processing genes among top signals; TRAF3IP2 encodes the IL‑17 signaling adaptor Act1; bone regulators DKK1/SOST vary with inflammatory signaling. URLs/Years: J Rheumatol 2024/2026; Arch Rheumatol 2025; Rheumatol Int 2023. (allardchamard2025exploringthegenetic pages 7-9, dilek2025immuneresponseand pages 1-2, dilek2025immuneresponseand pages 10-11) - Chemical entities: Small‑molecule JAK inhibitors and selective TYK2 inhibitors modulate the implicated cytokine circuits; anti‑IL‑17A/F, anti‑IL‑23p19, anti‑IL‑12/23p40, and anti‑TNF biologics validate the central axes. Current reviews outline mechanisms and therapeutic classes. (raychaudhuri2024jakstatsignalingand pages 1-3, dilek2025immuneresponseand pages 1-2) - Cell Types (CL): Th17/Tc17; γδ T cells; MAIT; ILC3; dendritic cells (including pDCs); synovial fibroblasts; osteoclasts/osteoblasts; macrophages, neutrophils, mast cells. These cells produce or respond to IL‑23/IL‑17/TNF, coordinate innate‑adaptive crosstalk, and drive tissue changes. (dilek2025immuneresponseand pages 1-2, dilek2025immuneresponseand pages 10-11, raychaudhuri2024jakstatsignalingand pages 1-3) - Anatomical locations (UBERON): Enthesis; synovium; nail–DIP unit; sacroiliac joint/spine. The nail–DIP anatomical linkage explains frequent co‑localization of nail disease and DIP arthritis in PsA. (mcgonagle2024grappa2023debate pages 1-2)

3) Biological processes (GO terms; disrupted in PsA) - IL‑23 signaling and Th17 differentiation/effector function (GO:0032622; GO:0072538); IL‑17‑mediated signaling (GO:0032612); JAK/STAT cascade (GO:0007259); TNF signaling via NF‑κB (GO:0033209); type I interferon signaling pathway (GO:0060337); antigen processing and presentation of endogenous peptide antigen via MHC class I (GO:0002474); osteoclast differentiation (GO:0030316); Wnt signaling pathway and negative regulation by DKK1/SOST (GO:0016055; GO:0030178). Mechanistic and therapy literature support these as central. (raychaudhuri2024jakstatsignalingand pages 1-3, dilek2025immuneresponseand pages 1-2, allardchamard2025exploringthegenetic pages 7-9)

4) Cellular components - Plasma membrane cytokine receptors (IL‑23R, IL‑17R, TNFR); cytoplasmic JAK/TYK/STAT signalosomes; nucleus (STAT‑dependent transcription); endoplasmic reticulum (ERAP1/2 peptide trimming); extracellular space (cytokines; DKK1/SOST; RANKL). (raychaudhuri2024jakstatsignalingand pages 1-3, allardchamard2025exploringthegenetic pages 7-9)

5) Disease progression (sequence of events) - Initiation: Genetic susceptibility (HLA‑B27; ERAP1/2; IL23R, IL12B, TYK2; TRAF3IP2) primes immune circuits. Mechanical microdamage at entheses and local innate sensing recruit myeloid/DC populations and innate‑like lymphocytes. (allardchamard2025exploringthegenetic pages 7-9, mcgonagle2024grappa2023debate pages 1-2) - Propagation: IL‑23 from myeloid cells sustains Th17/innate‑like IL‑17 producers (γδ T, MAIT, ILC3). IL‑17/TNF drive stromal activation (synovial fibroblasts), chemokine/MMP production, and recruitment of neutrophils/macrophages, culminating in synovitis and enthesitis. (dilek2025immuneresponseand pages 1-2, dilek2025immuneresponseand pages 10-11) - Structural change: RANKL‑driven osteoclastogenesis (erosion) occurs alongside Wnt pathway modulation by DKK1/SOST, enabling paradoxical osteoproliferation (enthesophytes, periosteal new bone). (dilek2025immuneresponseand pages 1-2, dilek2025immuneresponseand pages 10-11) - Spread and phenotypes: Nail unit inflammation spreads to the adjacent DIP enthesis/synovium; axial structures (sacroiliac/spine entheses) may be involved in axPsA. (mcgonagle2024grappa2023debate pages 1-2)

6) Phenotypic manifestations (with links to mechanisms) - Enthesitis (HP:0100715): Arises at mechanically stressed insertions, dominated by IL‑23/IL‑17 and innate‑like lymphocytes; central in PsA. (mcgonagle2024grappa2023debate pages 1-2, dilek2025immuneresponseand pages 10-11) - Dactylitis (HP:0005905): Represents a digit‑wide enthesitis/tenosynovitis composite; micro‑enthesis inflammation along pulleys contributes. (dilek2025immuneresponseand pages 10-11) - Synovitis (HP:0004315): Cytokine‑driven stromal and leukocyte activation within synovial tissue. (dilek2025immuneresponseand pages 1-2) - Axial disease/sacroiliitis (HP:0002826): Inflammation at spinal/sacroiliac entheses; response patterns reflect IL‑17/JAK axes. (mcgonagle2024grappa2023debate pages 1-2, raychaudhuri2024jakstatsignalingand pages 1-3) - Bone remodeling (erosion and new bone): RANKL induction and Wnt antagonism integrate inflammatory signaling with structural change. (dilek2025immuneresponseand pages 1-2)

7) Recent developments and latest research (2023–2024 priority) - Enthesitis‑first paradigm and synovio‑entheseal complex reinforced with clinical imaging and anatomical evidence; nail–DIP linkage and cytokine validation (IL‑17/IL‑23/TNF) emphasized in the 2024 GRAPPA debate summary (The Journal of Rheumatology, Aug 2024; DOI above). (mcgonagle2024grappa2023debate pages 1-2) - JAK/STAT and TYK2: 2024 reviews synthesize how IL‑23 and other cytokines signal through JAK2/TYK2/STAT3, aligning with clinical success of JAK/TYK2 inhibitors and next‑generation intracellular targets. (raychaudhuri2024jakstatsignalingand pages 1-3) - Cytokine network integration: Systematic review (2025, includes studies through 2024) details IL‑23/IL‑17, TNF, and their roles in osteoclastogenesis and new bone formation via DKK1/Wnt. (dilek2025immuneresponseand pages 1-2) - Bone remodeling biomarkers: 2023 review highlights variability of circulating DKK1 in PsA and calls for standardized methodologies—underscoring complexity of the inflammatory‑osteogenic axis. (dilek2025immuneresponseand pages 10-11) - Genetics (synthesis through 2025/2026): Aggregated genomic data implicate IL23R, IL12B, TYK2, TRAF3IP2, ERAP1/2, and HLA class I; enrichment of innate, antigen presentation, Th17, and interferon pathways highlight disease‑relevant biology and drug targetability. (allardchamard2025exploringthegenetic pages 7-9)

8) Current applications and real‑world implementations - Biologics targeting IL‑17A/F, IL‑23p19, IL‑12/23p40, and TNF are standard of care and mechanistically validate the dominant cytokine axes; JAK1‑selective and TYK2‑targeted therapies offer oral options that modulate IL‑23 family and interferon signaling. (raychaudhuri2024jakstatsignalingand pages 1-3, dilek2025immuneresponseand pages 1-2) - Clinical anatomy–guided care: Recognition of nail–DIP–enthesis linkage supports targeted assessment and therapeutic choice in DIP arthritis with nail psoriasis. (mcgonagle2024grappa2023debate pages 1-2) - Bone outcomes: Understanding of DKK1/SOST/Wnt balance informs interpretation of imaging and bone outcomes under anti‑TNF or anti‑IL‑17/23 therapy. (dilek2025immuneresponseand pages 10-11, dilek2025immuneresponseand pages 1-2)

9) Expert opinions and analysis (authoritative sources) - GRAPPA 2023 debate (published 2024) synthesizes two decades of enthesitis research, concluding that enthesis anatomy and imaging data strongly support a primary enthesitis model with cytokine drivers that are therapeutically tractable. (mcgonagle2024grappa2023debate pages 1-2) - Mechanistic rheumatology reviews (2024) argue for JAK/STAT as a unifying intracellular hub across multiple PsA‑relevant cytokines, motivating selective JAK/TYK2 inhibitor development to balance efficacy and safety. (raychaudhuri2024jakstatsignalingand pages 1-3)

10) Relevant statistics and data - Genetics synthesis: Non‑MHC variants account for a substantial proportion of psoriatic disease risk, with multiple protein‑altering signals in IL23R/TRAF3IP2/TYK2/IL12B and others; enrichment across innate, antigen presentation, Th17, and interferon pathways (quantitative counts provided in source review). (allardchamard2025exploringthegenetic pages 7-9) - Bone marker variability: Among 8 original studies, DKK1 serum levels in PsA were reported higher in 4, comparable in 1, and lower in 2 (reviewed up to Aug 2023), underscoring heterogeneity of bone pathway readouts. (dilek2025immuneresponseand pages 10-11)

Ontology‑ready annotations and evidence table |Entity Type|Name (ontology)|Role / Mechanism in PsA (1–2 sentences)|Phenotype link (HP)|Evidence|Source DOI / URL| |---|---|---|---|---|---| |Gene / Protein|HLA-B27 (HGNC:HLA-B)|MHC class I allele associated with PsA susceptibility and axial/enthesitic phenotypes; influences peptide presentation and interacts with ERAP-mediated peptide trimming to modulate inflammation.|Enthesitis; axial disease (HP:0002826)| (allardchamard2025exploringthegenetic pages 7-9, mcgonagle2024grappa2023debate pages 1-2)|doi:10.3899/jrheum.2025-0273; https://doi.org/10.3899/jrheum.2024-0593| |Gene / Protein|ERAP1/ERAP2 (HGNC:ERAP1 / ERAP2)|Endoplasmic reticulum aminopeptidases that trim peptides for HLA class I presentation; genetic variants modify antigen repertoire and PsA risk.|Immune dysregulation leading to arthritis| (allardchamard2025exploringthegenetic pages 7-9, gupta2025genomewidemetaanalysisand pages 21-24)|doi:10.3899/jrheum.2025-0273; https://doi.org/10.1101/2025.08.26.25334362| |Gene / Protein|IL23R (HGNC:IL23R)|Receptor for IL-23 that stabilizes/expands Th17 cells via STAT3 signaling, driving IL-17 production and tissue inflammation.|Synovitis, enthesitis, skin lesions| (allardchamard2025exploringthegenetic pages 7-9, dilek2025immuneresponseand pages 1-2)|doi:10.3899/jrheum.2025-0273; doi:10.46497/archrheumatol.2025.10934| |Gene / Protein|IL12B (HGNC:IL12B)|Encodes p40 subunit shared by IL-12 and IL-23; genetic variation affects IL-23–Th17 axis activity and therapeutic targeting (anti-p40 biologics).|Psoriasis with risk of PsA progression| (allardchamard2025exploringthegenetic pages 7-9, gupta2025genomewidemetaanalysisand pages 21-24)|doi:10.3899/jrheum.2025-0273; https://doi.org/10.1101/2025.08.26.25334362| |Gene / Protein|TYK2 (HGNC:TYK2)|Janus-family kinase involved in IL-23/Type I IFN signaling; genetic/functional modulation influences Th17/IFN pathways and is a therapeutic target (TYK2 inhibitors).|Modulates systemic inflammation and IL-23–driven pathology| (allardchamard2025exploringthegenetic pages 7-9, raychaudhuri2024jakstatsignalingand pages 1-3)|doi:10.3899/jrheum.2025-0273; doi:10.1007/s11926-024-01144-x| |Gene / Protein|TRAF3IP2 (HGNC:TRAF3IP2)|Adapter protein (Act1) in IL-17 receptor signaling; variants associate with PsA and amplify IL-17–mediated inflammatory cascades in skin and joint tissues.|Enhanced IL-17 responses; synovitis| (allardchamard2025exploringthegenetic pages 7-9)|doi:10.3899/jrheum.2025-0273| |Gene / Protein|DKK1 (HGNC:DKK1)|Wnt pathway antagonist regulating bone formation; altered DKK1 levels in PsA link inflammatory cytokines (TNF/IL-17) to dysregulated osteogenesis and erosion/new bone formation.|Bone remodeling imbalance; osteoproliferation| (dilek2025immuneresponseand pages 1-2)|doi:10.46497/archrheumatol.2025.10934| |Gene / Protein|RANKL / TNFSF11 (HGNC:TNFSF11)|Key osteoclast differentiation factor induced by inflammatory cytokines (IL-17, TNF), mediating bone resorption in erosive PsA.|Bone erosion (HP:0003009)| (dilek2025immuneresponseand pages 1-2)|doi:10.46497/archrheumatol.2025.10934| |Gene / Protein|SOST (HGNC:SOST)|Sclerostin, Wnt pathway inhibitor produced by osteocytes; inflammation can alter SOST/DKK1 balance contributing to paradoxical bone loss and formation in SpA/PsA.|Altered bone density/formation| (dilek2025immuneresponseand pages 1-2)|doi:10.46497/archrheumatol.2025.10934| |Cell Type|Th17 cell (CL:Th17)|Adaptive CD4+ subset driven by IL-23/STAT3/RORγt that secretes IL-17A/F and IL-22, promoting synovial inflammation, MMP production, and osteoclastogenesis.|Synovitis, enthesitis, bone damage| (dilek2025immuneresponseand pages 1-2, bonomo2025recentadvancesin pages 5-7)|doi:10.46497/archrheumatol.2025.10934; https://doi.org/10.3390/nu17081323| |Cell Type|Innate-like IL-17 sources (γδ T cells, MAIT, ILC3) (CL:gamma-delta / CL:MAIT / CL:ILC3)|Tissue-resident or mucosa-derived cells that rapidly produce IL-17 in response to IL-23/IL-1β and mechanical triggers, linking mucosal/gut signals to joint inflammation.|Rapid local IL-17 release; enthesitis/dactylitis| (dilek2025immuneresponseand pages 10-11, bonomo2025recentadvancesin pages 5-7)|doi:10.46497/archrheumatol.2025.10934; https://doi.org/10.3390/nu17081323| |Cell Type|Plasmacytoid dendritic cell (pDC) (CL:pDC)|Major source of type I IFNs; pDC activation and IFN signatures can modulate TNF/IL-23 axes and affect treatment responses and local immune priming.|IFN-associated inflammation; therapy-refractory signatures| (bonomo2025recentadvancesin pages 4-5, dilek2025immuneresponseand pages 1-2)|https://doi.org/10.3390/nu17081323; doi:10.46497/archrheumatol.2025.10934| |Cell Type|Synovial fibroblast (CL:synovial fibroblast)|Stromal effector cells that respond to IL-17/TNF by producing cytokines, chemokines and MMPs, sustaining synovial pannus, leukocyte recruitment and tissue destruction.|Chronic synovitis and cartilage damage| (bonomo2025recentadvancesin pages 4-5, dilek2025immuneresponseand pages 10-11)|https://doi.org/10.3390/nu17081323; doi:10.46497/archrheumatol.2025.10934| |Cell Type|Osteoclast / Osteoblast (CL:osteoclast / CL:osteoblast)|Osteoclasts (RANKL-driven) mediate bone erosion; osteoblasts and Wnt inhibitors (DKK1/SOST) control reparative/new bone formation, producing the mixed bone phenotype in PsA.|Bone erosion and osteoproliferation| (dilek2025immuneresponseand pages 1-2, bonomo2025recentadvancesin pages 5-7)|doi:10.46497/archrheumatol.2025.10934; https://doi.org/10.3390/nu17081323| |Cell Type|Innate myeloid cells (macrophage, neutrophil, mast cell)|Provide IL-1, TNF, IL-6 and extrafollicular IL-17 (e.g., from neutrophil NETs/mast cells), amplifying local inflammation and matrix degradation.|Synovitis, enthesitis, neutrophil-driven flares| (bonomo2025recentadvancesin pages 5-7, dilek2025immuneresponseand pages 1-2)|https://doi.org/10.3390/nu17081323; doi:10.46497/archrheumatol.2025.10934| |Anatomical Site|Enthesis (UBERON:enthesis)|Site of tendon/ligament insertion with specialized microanatomy; microdamage/mechanical stress triggers local innate immunity and IL-23/IL-17–mediated enthesitis that can extend to synovium (synovio-entheseal complex).|Enthesitis (HP:0100715), dactylitis (HP:0005905)| (mcgonagle2024grappa2023debate pages 1-2, dilek2025immuneresponseand pages 10-11)|doi:10.3899/jrheum.2024-0593; doi:10.46497/archrheumatol.2025.10934| |Anatomical Site|Synovium (UBERON:synovium)|Primary site of inflammatory pannus formation; cytokine-rich synovium contains infiltrating Th17/innate cells and activated fibroblasts driving joint symptoms.|Synovitis (HP:0004315)| (dilek2025immuneresponseand pages 10-11, bonomo2025recentadvancesin pages 4-5)|doi:10.46497/archrheumatol.2025.10934; https://doi.org/10.3390/nu17081323| |Anatomical Site|Nail–DIP unit (anatomical link)|Anatomical continuity between nail matrix and distal interphalangeal (DIP) enthesis explains frequent co-occurrence of nail disease and DIP joint involvement in PsA.|DIP arthritis; nail changes preceding PsA| (mcgonagle2024grappa2023debate pages 1-2, bonomo2025recentadvancesin pages 4-5)|doi:10.3899/jrheum.2024-0593; https://doi.org/10.3390/nu17081323| |Anatomical Site|Sacroiliac joint (UBERON:sacroiliac joint)|Axial manifestations of PsA (axial PsA) involve sacroiliac/spinal entheses and may show distinct genetics/therapy responses from AS.|Axial disease; sacroiliitis| (mcgonagle2024grappa2023debate pages 1-2, bonomo2025recentadvancesin pages 4-5)|doi:10.3899/jrheum.2024-0593; https://doi.org/10.3390/nu17081323| |Pathway / Process|IL-23 / IL-17 signaling (GO:0032622) & JAK/STAT (GO:0007259)|IL-23 stabilizes Th17 cells (STAT3/TYK2/JAK2-mediated); IL-17 acts on stromal cells to induce NF-κB/MMPs; JAK/STAT signaling integrates multiple cytokine inputs and is a therapeutic axis (JAK/TYK2 inhibitors).|Drives Th17-mediated synovitis, enthesitis; therapeutic target| (dilek2025immuneresponseand pages 1-2, raychaudhuri2024jakstatsignalingand pages 1-3, bonomo2025recentadvancesin pages 5-7)|doi:10.46497/archrheumatol.2025.10934; doi:10.1007/s11926-024-01144-x; https://doi.org/10.3390/nu17081323| |Chemical / Drug (Therapy)|JAK / TYK2 inhibition (e.g., JAKi, TYK2 inhibitors)|Small-molecule inhibitors that blunt JAK-mediated cytokine signaling (including IL-23/IL-12 family effects via TYK2) and reduce both skin and joint inflammation; emerging data support efficacy in PsA and enthesitis.|Therapeutic modulation of synovitis/enthesitis| (raychaudhuri2024jakstatsignalingand pages 1-3, dilek2025immuneresponseand pages 1-2)|doi:10.1007/s11926-024-01144-x; doi:10.46497/archrheumatol.2025.10934|

Table: A compact ontology-ready table summarizing genes/proteins, cells, anatomical sites, pathways and therapies implicated in psoriatic arthritis pathophysiology, with concise mechanisms, phenotype links (HP terms) and evidence citations to the gathered sources for knowledge‑base integration.

Evidence items (with URLs/dates when available) - McGonagle D, Abacar K, Kirkham B. GRAPPA 2023 Debate: Is Psoriatic Disease Really a Primary Enthesitis… The Journal of Rheumatology. Aug 2024. doi:10.3899/jrheum.2024-0593 (mcgonagle2024grappa2023debate pages 1-2) - Raychaudhuri SP, Shah RJ, Banerjee S, Raychaudhuri SK. JAK-STAT Signaling and Beyond in the Pathogenesis of Spondyloarthritis… Current Rheumatology Reports. Mar 2024. doi:10.1007/s11926-024-01144-x (raychaudhuri2024jakstatsignalingand pages 1-3) - Dilek G, Unan MK, Nas K. Immune response and cytokine pathways in psoriatic arthritis: A systematic review. Archives of Rheumatology. Mar 2025. doi:10.46497/archrheumatol.2025.10934 (dilek2025immuneresponseand pages 1-2) (dilek2025immuneresponseand pages 10-11) - Biedroń G, et al. Serum concentration of DKK1 in psoriatic arthritis. Rheumatology International. Sep 2023. doi:10.1007/s00296-023-05452-w (dilek2025immuneresponseand pages 10-11) - Allard‑Chamard H, Rahman P. Exploring the genetic landscape of PsA: A narrative review. The Journal of Rheumatology. Aug 2026. doi:10.3899/jrheum.2025-0273 (genetics synthesis spanning up to 2025). (allardchamard2025exploringthegenetic pages 7-9) - Additional mechanistic overviews on microbiome/innate–adaptive crosstalk used cautiously (Nutrients 2025 narrative review) to contextualize IL‑23/JAK/STAT and cell‑type roles. Apr 2025. doi:10.3390/nu17081323 (bonomo2025recentadvancesin pages 5-7, bonomo2025recentadvancesin pages 4-5)

Gene/protein, cell, and phenotype annotations for knowledge base integration - HGNC: HLA‑B; ERAP1; ERAP2; IL23R; IL12B; TYK2; TRAF3IP2; DKK1; TNFSF11 (RANKL); SOST. (allardchamard2025exploringthegenetic pages 7-9, dilek2025immuneresponseand pages 1-2, dilek2025immuneresponseand pages 10-11) - CL: Th17 cell; γδ T cell; MAIT cell; ILC3; plasmacytoid dendritic cell; synovial fibroblast; osteoclast; osteoblast; macrophage; neutrophil; mast cell. (dilek2025immuneresponseand pages 1-2, dilek2025immuneresponseand pages 10-11) - UBERON: Enthesis; Synovium; Distal interphalangeal joint/nail unit; Sacroiliac joint. (mcgonagle2024grappa2023debate pages 1-2) - GO (selected): IL‑23 signaling/Th17 differentiation (GO:0032622/GO:0072538); IL‑17 signaling (GO:0032612); JAK/STAT (GO:0007259); TNF→NF‑κB (GO:0033209); type I IFN signaling (GO:0060337); antigen processing MHC I (GO:0002474); osteoclast differentiation (GO:0030316); Wnt signaling regulation (GO:0016055/GO:0030178). (raychaudhuri2024jakstatsignalingand pages 1-3, dilek2025immuneresponseand pages 1-2, allardchamard2025exploringthegenetic pages 7-9) - HP: Enthesitis (HP:0100715); Dactylitis (HP:0005905); Synovitis (HP:0004315); Axial disease/sacroiliitis (HP:0002826); Bone erosion (HP:0003009). (mcgonagle2024grappa2023debate pages 1-2, dilek2025immuneresponseand pages 10-11, dilek2025immuneresponseand pages 1-2)

Conclusions PsA pathophysiology is best conceptualized as an enthesis‑initiated, cytokine‑amplified process integrated through JAK/STAT signal transduction and sculpted by genetic variation in antigen presentation and IL‑23/Th17 pathways. This framework explains clinical phenotypes (enthesitis, dactylitis, axial disease), nail–DIP co‑involvement, and bone remodeling paradoxes, and it underpins current targeted therapies (anti‑IL‑17/23/TNF; JAK/TYK2 inhibitors). Future refinement will benefit from standardized bone biomarker assessment (e.g., DKK1), deeper resolution of cell states across the synovio‑entheseal complex, and genetics‑informed patient stratification. (mcgonagle2024grappa2023debate pages 1-2, raychaudhuri2024jakstatsignalingand pages 1-3, dilek2025immuneresponseand pages 10-11, dilek2025immuneresponseand pages 1-2, allardchamard2025exploringthegenetic pages 7-9)

References

1. (mcgonagle2024grappa2023debate pages 1-2): Dennis McGonagle, Kerem Abacar, and Bruce Kirkham. Grappa 2023 debate: is psoriatic disease really a primary enthesitis that drives joint synovitis? the enthesitis hypothesis 25 years on. The Journal of rheumatology, 51:101-105, Aug 2024. URL: https://doi.org/10.3899/jrheum.2024-0593, doi:10.3899/jrheum.2024-0593. This article has 5 citations.

2. (raychaudhuri2024jakstatsignalingand pages 1-3): Siba P. Raychaudhuri, Ruchi J. Shah, Sneha Banerjee, and Smriti K. Raychaudhuri. Jak-stat signaling and beyond in the pathogenesis of spondyloarthritis and their clinical significance. Current Rheumatology Reports, 26:204-213, Mar 2024. URL: https://doi.org/10.1007/s11926-024-01144-x, doi:10.1007/s11926-024-01144-x. This article has 17 citations and is from a peer-reviewed journal.

3. (dilek2025immuneresponseand pages 1-2): Gamze Dilek, Mehtap Kalcik Unan, and Kemal Nas. Immune response and cytokine pathways in psoriatic arthritis: a systematic review. Archives of Rheumatology, 40:144-156, Mar 2025. URL: https://doi.org/10.46497/archrheumatol.2025.10934, doi:10.46497/archrheumatol.2025.10934. This article has 6 citations.

4. (dilek2025immuneresponseand pages 10-11): Gamze Dilek, Mehtap Kalcik Unan, and Kemal Nas. Immune response and cytokine pathways in psoriatic arthritis: a systematic review. Archives of Rheumatology, 40:144-156, Mar 2025. URL: https://doi.org/10.46497/archrheumatol.2025.10934, doi:10.46497/archrheumatol.2025.10934. This article has 6 citations.

5. (allardchamard2025exploringthegenetic pages 7-9): Hugues Allard-Chamard and Proton Rahman. Exploring the genetic landscape of psoriatic arthritis: a narrative review of recent genomic studies. The Journal of rheumatology, Aug 2026. URL: https://doi.org/10.3899/jrheum.2025-0273, doi:10.3899/jrheum.2025-0273. This article has 0 citations.

6. (bonomo2025recentadvancesin pages 5-7): Maria Grazia Bonomo, Salvatore D’Angelo, Valentina Picerno, Antonio Carriero, and Giovanni Salzano. Recent advances in gut microbiota in psoriatic arthritis. Nutrients, 17:1323, Apr 2025. URL: https://doi.org/10.3390/nu17081323, doi:10.3390/nu17081323. This article has 7 citations and is from a poor quality or predatory journal.

7. (bonomo2025recentadvancesin pages 4-5): Maria Grazia Bonomo, Salvatore D’Angelo, Valentina Picerno, Antonio Carriero, and Giovanni Salzano. Recent advances in gut microbiota in psoriatic arthritis. Nutrients, 17:1323, Apr 2025. URL: https://doi.org/10.3390/nu17081323, doi:10.3390/nu17081323. This article has 7 citations and is from a poor quality or predatory journal.

8. (gupta2025genomewidemetaanalysisand pages 21-24): Yask Gupta, Tatiana Sezin, and Diamant Thaçi. Genome-wide meta-analysis and integrative fine-mapping identify novel susceptibility loci and effector genes in psoriatic arthritis. MedRxiv, Aug 2025. URL: https://doi.org/10.1101/2025.08.26.25334362, doi:10.1101/2025.08.26.25334362. This article has 0 citations.

Comprehensive Pathophysiology of Psoriatic Arthritis: Molecular, Cellular, and Clinical Mechanisms

Psoriatic arthritis (PsA) represents a complex inflammatory musculoskeletal disease characterized by the disruption of both innate and adaptive immune homeostasis, resulting in chronic joint inflammation, cartilage and bone destruction, and new bone formation. Recent advances in molecular profiling and mechanistic studies have revealed that PsA develops through the interplay of genetic susceptibility, environmental triggers, and dysregulated immune activation targeting multiple anatomical sites including synovial joints, the enthesis (site of tendon and ligament insertion), and skin. The disease emerges in approximately thirty percent of patients with psoriasis vulgaris, typically between five to twelve years following initial skin manifestations, though concurrent or sequential skin and joint disease presentations occur frequently. This comprehensive analysis synthesizes current understanding of the pathophysiological mechanisms driving PsA across multiple biological scales, from molecular signaling pathways to tissue-level inflammation and systemic immune dysregulation.

Genetic Architecture and Susceptibility Loci Underlying Psoriatic Arthritis

The genetic foundation of psoriatic arthritis demonstrates substantially higher heritability than its cutaneous-only counterpart, with sibling recurrence risks (λS) estimated between twenty-seven to forty-seven, compared to the four to nineteen observed for psoriasis vulgaris alone[7][9]. This striking difference in genetic contribution indicates that specific genetic variants confer arthritis-specific risk beyond those associated with skin disease alone. Genome-wide association studies encompassing over thirty-six thousand cases and four hundred fifty-eight thousand controls have identified one hundred nine distinct psoriasis susceptibility loci, with approximately forty-five newly identified variants, though the distinction between PsA-specific and psoriasis-shared genetic factors remains an active area of investigation[12].

The major histocompatibility complex region demonstrates the strongest association signals with PsA, particularly at chromosome 6p21 approximately thirty-five kilobases upstream of the HLA-C gene[7][10]. The HLA-C06:02 allele exhibits strong association with psoriasis vulgaris but shows weaker association with PsA, suggesting divergent genetic architecture between cutaneous and articular manifestations[9]. Conversely, HLA-B27 displays stronger association with PsA, particularly in patients with axial skeletal involvement, though at substantially lower frequency than observed in ankylosing spondylitis[20]. These HLA class I associations underscore the critical role of CD8+ T cell recognition and response in PsA pathogenesis, as these molecules present peptide antigens to CD8+ T cells.

Beyond the HLA complex, multiple non-MHC loci contribute to PsA susceptibility through diverse immunological mechanisms. The IL23R locus demonstrates genome-wide significant association with PsA, encoding the receptor for interleukin-23, a critical driver of T helper 17 (Th17) cell differentiation and inflammatory cytokine production[7][12]. The IL12B region harbors multiple independent susceptibility variants, reflecting the importance of IL-23/IL-17 axis dysregulation in PsA pathogenesis[9]. Additional susceptibility loci include TNIP1, TNFAIP3, NFκBIA, and TYK2, which encode molecules involved in NF-κB signaling, TNF-α pathway modulation, and JAK/STAT signaling, respectively, highlighting the convergence of multiple inflammatory pathways in PsA[7][12].

The REL locus, encoding the c-Rel member of the NF-κB family, demonstrates PsA-specific association stronger than observed for psoriasis vulgaris alone[7][10]. This finding implicates NF-κB-dependent transcription particularly in joint inflammation and suggests that innate immune pathway dysregulation through altered transcription factor activity constitutes a core PsA mechanism. The identification of multiple independent PsA susceptibility variants within regions such as IL12B, NOS2, and IFIH1 indicates complex allelic architecture with distinct functional consequences for each variant, requiring comprehensive functional characterization to fully understand their contributions to disease[9].

The IL-23/IL-17 Axis: Central Orchestrator of Inflammatory Pathology

The interleukin-23 and interleukin-17 signaling axis has emerged as the dominant cytokine pathway driving PsA pathogenesis, building upon extensive evidence from genetic association studies, animal models, and clinical treatment responses[3][4]. This pathway initiates at the level of antigen-presenting cells, particularly dendritic cells resident in skin, enthesis, and synovial tissues, where stimulation triggers the release of multiple pro-inflammatory cytokines that work in concert to promote Th17 cell differentiation and expansion[3][4].

Upon encountering inflammatory stimuli, dendritic cells release interleukin-23, interleukin-12, interleukin-1β, and tumor necrosis factor-alpha, which collectively promote the differentiation of naive CD4+ T cells into T helper 17 cells[3][4]. Interleukin-23 binding to its heterodimeric receptor composed of IL-23R and IL-12Rβ1 chains activates the JAK2 and Tyk2 protein tyrosine kinases, which phosphorylate signal transducer and activator of transcription 3 (STAT3) at tyrosine 705[3][4]. Phosphorylated STAT3 translocates to the nucleus where it induces expression of RORγ (RAR-related orphan receptor gamma), the master transcription factor controlling Th17 differentiation and IL-17 production[3][4]. This initial differentiation also requires transforming growth factor-beta and interleukin-6 signaling, which together with IL-23 support sustained IL-17 production[3].

The Th17 subset of CD4+ T cells serves as a primary source of interleukin-17A, the prototypical member of the IL-17 cytokine family[3][4]. Studies utilizing flow cytometry and intracellular cytokine staining consistently demonstrate increased frequencies of Th17 cells in the peripheral blood, synovial fluid, and synovial tissue of PsA patients compared with healthy controls and osteoarthritis patients[5][3]. This expanded Th17 population releases an array of pro-inflammatory cytokines including IL-17A, IL-17B, IL-17F, IL-21, IL-22, and IL-26, which amplify downstream inflammatory responses[3][4].

Interleukin-17 exerts pleiotropic effects on multiple effector cell types within the joint microenvironment[3][4]. IL-17A stimulation of synovial fibroblasts induces their proliferation and upregulation of matrix metalloproteinases (particularly MMP-1, MMP-3, and MMP-13) that degrade cartilage extracellular matrix components[3]. Synovial fibroblasts activated by IL-17 further produce chemokines including CXCL1, CXCL2, CXCL5, and CXCL8, which promote recruitment of neutrophils and additional myeloid cells to inflamed joints[3]. The actions of IL-17 extend to skeletal cells, where IL-17A increases expression of receptor activator of nuclear factor kappa-B ligand (RANKL) on both fibroblasts and Th17 cells themselves, leading to enhanced osteoclast precursor differentiation and bone-resorbing osteoclast maturation[3][4]. Paradoxically, IL-17 also appears to promote osteoblast differentiation through mechanisms involving IL-22 signaling, contributing to the distinctive pattern of bone erosion coupled with new bone formation characteristic of PsA[3][4].

The IL-23/IL-17 axis effects extend beyond CD4+ T cells, as gamma-delta T cells (γδT cells) represent an additional IL-17 source in PsA. These innate-like lymphocytes express the IL-23 receptor and rapidly produce IL-17 upon IL-23 stimulation, providing an early source of this cytokine during inflammation[3][5]. Gamma-delta T cells express chemokine receptors CCR6 and CCR2, which direct them to skin and synovial sites in response to CCL6 and CCL2 gradients[5]. Natural killer T cells and mucosal-associated invariant T (MAIT) cells also contribute to IL-17 production in PsA synovium and psoriatic skin[5]. This multiplicity of IL-17-producing cell types ensures sustained inflammatory responses even when one population is incompletely controlled by therapy.

Interleukin-22, another product of Th17 and related T cell subsets, plays a distinct role in PsA pathogenesis through effects on keratinocyte hyperproliferation and bone homeostasis[3][4]. IL-22 signaling through its heterodimeric receptor on keratinocytes downregulates differentiation genes while promoting proliferation and expression of antimicrobial peptides[3]. Within the joint, IL-22 promotes osteoblast differentiation through STAT3-mediated signaling and upregulation of bone morphogenetic protein pathways, leading to the paradoxical new bone formation observed at entheseal sites and within synovial tissue[3][4]. This simultaneous bone erosion and formation distinguishes PsA from rheumatoid arthritis, where erosions typically predominate without significant periosteal or enthesal new bone formation.

The IL-23/IL-17 axis operates within a complex inflammatory milieu, with considerable cross-talk and synergistic interactions with other pro-inflammatory pathways. Tumor necrosis factor-alpha, discussed in detail below, synergizes with IL-17A to amplify inflammatory responses through combined effects on endothelial cells, fibroblasts, and immune cell recruitment[3][4]. The combination of TNF-α and IL-17A induces greater expression of adhesion molecules (ICAM-1, VCAM-1, P-selectin, E-selectin) on endothelial cells than either cytokine alone, facilitating enhanced leukocyte extravasation into inflamed tissues[3].

TNF-α Pathway: Amplification and Tissue Destruction

Tumor necrosis factor-alpha, a prototypical pro-inflammatory cytokine, reaches elevated concentrations in PsA serum, synovial fluid, and synovial tissue, where it drives multiple aspects of inflammatory joint disease[5]. TNF-α expression predominantly derives from activated macrophages, T cells, and other myeloid cells within the inflamed synovium, though keratinocytes, dendritic cells, and fibroblasts also contribute to systemic and local TNF-α production[5]. The biological effects of TNF-α occur through binding to two distinct receptors, TNF receptor 1 (TNFR1, p55 subunit) and TNF receptor 2 (TNFR2, p75 subunit), which activate different downstream signaling cascades and produce divergent cellular outcomes[5].

TNFR1 activation triggers both pro-inflammatory and pro-apoptotic signaling pathways, leading to NF-κB and mitogen-activated protein kinase (MAPK) pathway activation with consequent inflammatory cytokine production and induction of cell death receptors[5]. TNF-α stimulation of synovial fibroblasts increases their expression of IL-6, IL-8, and granulocyte-macrophage colony-stimulating factor (GM-CSF), amplifying the pro-inflammatory milieu[5]. TNF-α also stimulates synovial fibroblasts to produce additional matrix metalloproteinases and tissue inhibitors of metalloproteinases, with the net effect being enhanced cartilage degradation when MMP production exceeds TIMP production[3][5].

The role of TNF-α extends critically to bone remodeling in PsA, where it exerts complex effects on osteoclast and osteoblast biology[5]. TNF-α stimulates RANKL expression in bone marrow stromal cells and activates p38 mitogen-activated protein kinase signaling, leading to increased c-Fms expression and enhanced responsiveness of osteoclast precursors to M-CSF (macrophage colony-stimulating factor)[5]. TNF-α additionally activates TRAF6, a critical adaptor molecule in RANK signaling essential for osteoclastogenesis[5]. The combination of TNF-α-induced RANKL upregulation and enhanced osteoclast precursor sensitivity creates a permissive environment for accelerated bone loss[5].

Studies of PsA peripheral blood mononuclear cells have demonstrated elevated frequencies of circulating osteoclast precursors in unstimulated cultures, with particularly high numbers in patients with radiographically evident bone erosions[28]. The elevated TNF-α produced by PsA peripheral blood mononuclear cells can independently induce these precursor cells to differentiate into mature osteoclasts, an effect blocked by anti-TNF-α monoclonal antibodies[28]. These findings establish a mechanistic link between elevated TNF-α and the aggressive bone erosions characteristic of PsA.

TNF-α simultaneously inhibits the Wnt signaling pathway critical for bone formation through upregulation of Dickkopf-1 (DKK-1) and sclerostin, factors that antagonize the Wnt receptor complex[3][4]. This TNF-α-mediated suppression of bone formation through Wnt pathway inhibition contrasts with the IL-17/IL-22-mediated promotion of bone formation, creating the distinctive radiographic pattern of PsA with both erosive and proliferative bone lesions[3][4].

The effectiveness of TNF-α inhibitor therapy in controlling both skin and joint manifestations of PsA validates TNF-α as a central therapeutic target, though approximately thirty to forty percent of patients demonstrate inadequate response or loss of response to TNF-α inhibitor monotherapy[6]. This variable responsiveness has prompted investigation into combination approaches and alternative cytokine targets, including IL-17 and IL-23 inhibitors that may be more effective in TNF-α-inadequate responders.

JAK/STAT Signaling: Integration of Cytokine Pathways

The Janus kinase-signal transducer and activator of transcription (JAK/STAT) pathway integrates signals from multiple cytokines including IL-6, IL-17, IL-23, interferons, and type I interferons, serving as a crucial convergence point for inflammatory signaling in PsA[1][3]. Recent research has unveiled previously unappreciated roles of JAK/STAT signaling in driving synovial cell proliferation and pannus formation beyond its established role in T cell differentiation[1].

In the context of PsA, T cells infiltrating joint tissue release inflammatory cytokines that activate JAK/STAT signaling in synovial lining cells[1]. The JAK enzyme family members JAK1, JAK2, and Tyk2 become phosphorylated upon receptor engagement, which in turn phosphorylate STAT proteins on critical tyrosine residues, promoting their dimerization and nuclear translocation[1][3]. Research conducted at UC Davis Health demonstrated that when this pathway becomes activated in synovial cells, it drives their abnormal proliferation and contributes to pannus formation, the invasive fibrovascular tissue that erodes cartilage and bone[1].

Specifically, IL-9 and IL-22 cytokines have been shown to activate JAK/STAT signaling in synovial cells, promoting their proliferation[1][3]. Studies using JAK inhibitors revealed that blocking JAK kinase activity reduces both synovial cell proliferation and the subsequent pannus formation and joint damage[1]. This finding has important therapeutic implications, as JAK inhibitors available for clinical use (including tofacitinib, baricitinib, and upadacitinib) may exert benefits through both immune cell modulation and direct effects on synovial cell biology[1].

The STAT3 protein, downstream of JAK activation, has emerged as a critical transcription factor in PsA pathogenesis[37]. STAT3 phosphorylation at tyrosine 705 is required for homodimer formation and optimal transcriptional activity[37]. In addition to its role in Th17 differentiation, STAT3 drives expression of pro-inflammatory cytokines including IL-6, IL-8, IL-23, and IL-17 in multiple cell types[37]. Studies of transgenic mice with constitutively active STAT3 in CD4+ T cells demonstrated development of spontaneous psoriasis-like arthritis, validating the pathogenic role of STAT3 hyperactivation[37]. Furthermore, individuals with higher STAT3 transcriptional activity in CD4+ T cells displayed increased susceptibility to joint disease, indicating that genetic variation affecting STAT3 function may contribute to PsA risk[37].

Innate Immune Cell Populations: Macrophages, Dendritic Cells, and Neutrophils

The innate immune response in PsA involves multiple cell types that serve as primary drivers of inflammation before, during, and in coordination with adaptive immune responses. Macrophages accumulate within PsA synovium where they produce abundant pro-inflammatory cytokines and growth factors[30]. Immunohistochemical studies reveal marked macrophage infiltration particularly in the synovial sublining layer, where CD68+ macrophages correlate with disease activity[30]. Macrophages in the PsA joint exhibit polarization toward a pro-inflammatory M1 phenotype that secretes TNF-α, IL-1β, IL-6, IL-12, and IL-23, supporting ongoing Th17 responses[30]. Additionally, activated macrophages produce matrix metalloproteinases including MMP-9, which directly degrade cartilage components and facilitate immune cell infiltration[30].

Dendritic cells serve as critical antigen-presenting cells that bridge innate and adaptive immunity in PsA[2][15]. A specialized subset of monocyte-derived dendritic cells (Mo-DCs) has been identified in PsA synovial fluid, characterized by expression of CD14, CD209 (DC-SIGN), and classical dendritic cell markers HLA-DR and CD11c[18]. These CD209+/CD14+ dendritic cells are significantly enriched in the inflamed joint compared with peripheral blood[18]. Within the synovium, dendritic cells present antigen to naive T cells and provide critical co-stimulatory signals through expression of CD40, CD80, and CD86 molecules[18]. Dendritic cells within PsA tissue release high concentrations of IL-23, IL-12, and TNF-α, which together drive Th17 cell differentiation[3].

Recent single-cell transcriptomic analysis of synovial fluid from PsA patients revealed profound alterations in the myeloid compartment, with elevated expression of proinflammatory genes and an interferon-induced signature[2][15]. Type 2 conventional dendritic cells and monocytes were identified as particularly activated, expressing high levels of molecules involved in antigen presentation and immune activation[2][15]. Notably, in patients whose PsA proved refractory to standard disease-modifying antirheumatic drugs, elevated expression of genes associated with the immunoproteasome and major histocompatibility complex class I molecules was identified as a major distinguishing feature[2][15]. This finding suggests that enhanced antigen presentation capacity through both classical and immunoproteasome-mediated pathways may contribute to treatment resistance, potentially through amplification of CD8+ T cell responses.

Neutrophils accumulate in PsA synovium at substantially higher frequencies than observed in rheumatoid arthritis[30]. Polymorphonuclear cells infiltrate the synovial tissue where they produce pro-inflammatory cytokines and form neutrophil extracellular traps (NETs), web-like structures released when neutrophils undergo a specialized form of cell death[27][30]. These NETs trap microbial pathogens and autoantigens while releasing proteolytic enzymes and antimicrobial peptides that can damage host tissues[27][30]. IL-17 enhances neutrophil recruitment through upregulation of endothelial adhesion molecules and production of chemokines, particularly CXCL8 (IL-8)[27][30]. Chronic neutrophil activation and NET formation have been proposed to contribute to PsA pathogenesis through sustained tissue damage and perpetuation of the inflammatory cascade[27][30].

Mast cells represent a previously underappreciated cellular component particularly enriched in PsA synovium compared with rheumatoid arthritis[30]. These cells are characterized by prominent IL-17A production and constitute a major cellular source of IL-17 within PsA synovial tissue[30]. Mast cells release multiple inflammatory mediators including prostaglandins, leukotrienes, growth factors (platelet-derived growth factor, fibroblast growth factor, vascular endothelial growth factor), and pro-inflammatory cytokines upon activation[3][30]. The IL-17A stored within mast cells may be rapidly mobilized during inflammation, serving a sentinel function in providing early IL-17A signaling during tissue inflammatory responses[30].

Synovial Fibroblasts: From Structural Cells to Invasive Effector Cells

Fibroblast-like synoviocytes (FLS) line the synovial membrane and normally maintain joint homeostasis by producing lubricating hyaluronic acid, structural proteins, and growth factors[30]. In PsA, these cells undergo phenotypic transformation and acquire invasive properties, contributing to pannus formation and joint destruction. Synovial fibroblasts in PsA proliferate abnormally, demonstrating reduced apoptosis and increased expression of anti-apoptotic proteins including Bcl-2[44]. IL-17 signaling substantially enhances fibroblast survival through STAT3-mediated upregulation of Bcl-2 and suppression of pro-apoptotic molecules[44].

The activated FLS phenotype in PsA involves marked upregulation of adhesion molecules, growth factors, and proteolytic enzymes. Synovial fibroblasts produce abundant matrix metalloproteinases including MMP-1 (collagenase), MMP-3 (stromelysin), and MMP-13 (collagenase-3), which directly degrade collagen and proteoglycan components of cartilage[26]. TNF-α and IL-1β serve as potent activators of FLS MMP production, with IL-1β particularly effective at stimulating MMP-3 synthesis[26]. The expression of these collagenases within pannus tissue at the cartilage-pannus junction correlates with radiographic evidence of cartilage erosion[26].

Beyond matrix degradation, synovial fibroblasts produce chemokines critical for immune cell recruitment including CCL2, CCL5, CXCL12, CXCL13, and CXCL16, which promote T cell and B cell infiltration[43]. Fibroblasts further express CCL20, the ligand for CCR6, which preferentially recruits Th17 cells, creating a self-amplifying inflammatory loop[43]. Recent studies employing single-cell transcriptomics have identified distinct fibroblast subsets with specific inflammatory signatures in PsA synovium[4]. A WNT5A+/IL24+ fibroblast subset has been identified as particularly inflammatory, located in proximity to activated keratinocytes and expressing high levels of inflammatory mediators[17].

Importantly, synovial fibroblasts undergo dynamic phenotypic changes during response to anti-inflammatory therapy. Studies demonstrate that effective IL-17A and TNF-α blockade leads to phenotypic switching from a destructive IL-6+/MMP3+/THY1+ subset toward a CD200+/DKK3+ phenotype with resolution-promoting properties[4]. This fibroblast plasticity suggests that successful therapeutics may work partially through reprogramming of synovial fibroblasts toward tissue-protective rather than tissue-destructive states.

CD8+ T Cells and Tissue-Resident Memory T Cells: Linking Skin and Joint Inflammation

While CD4+ T cells and Th17 differentiation have classically dominated discussions of PsA pathogenesis, accumulating evidence indicates that CD8+ T cells play critical roles in both cutaneous and articular manifestations of the disease. Human leukocyte antigen class I presentation of peptides to CD8+ T cells has been genetically linked to PsA development, with HLA-C06:02 and HLA-B27 alleles showing strong associations with disease[13][20]. Recent advances in single-cell transcriptomics have revealed enrichment of CD8+ tissue-resident memory T (Trm) cells in both psoriatic skin and PsA synovium[50][53].

Studies comparing CD8+ T cell phenotypes between skin and joint compartments demonstrate that tissue-resident memory CD8+ cells (characterized by expression of CD69 and lack of CD45RA) exhibit a stronger IL-17 signature in skin compared with joint tissue[50][53]. Importantly, these studies identified CD8+ T cell clones that are shared between skin and joint compartments, with a median of thirteen percent of skin CD8+ T cell receptors also present in joint tissue, and eight percent of joint CD8+ T cells found in skin[50][53]. These skin-joint shared clones typically maintain a similar CD8+ Trm phenotype at both sites, characterized by increased expression of cytotoxic genes and genes associated with tissue residency[50][53]. This clonal sharing provides direct evidence for trafficking of specific T cells between skin and joint compartments and suggests that targeting of shared antigens by these clones may drive inflammation across both tissue sites.

Patients with mild-to-moderate psoriasis demonstrate altered CD8+ T cell functionality, with reduced frequencies of circulating CD8+ memory T cells and decreased release of cytotoxic mediators (Granzyme B, IFN-γ) upon T cell receptor stimulation[8]. These alterations suggest that psoriatic disease involves dysregulation of CD8+ T cell activation and effector functions. The reduction of circulating CD8+ memory cells may reflect their migration into inflamed skin and joints, consistent with the elevated frequencies observed within these tissues[8].

Bone Remodeling: The Distinctive Pattern of Erosion with New Bone Formation

A pathognomonic feature of PsA distinguishing it from rheumatoid arthritis is the simultaneous occurrence of bone erosion and new bone formation, often within the same joint or even the same digit[20][29]. This uncoupling of osteoblast and osteoclast homeostasis creates the characteristic "pencil-in-cup" deformity and periosteal reactions visible on radiographs. Understanding the cellular and molecular basis of this paradoxical bone remodeling requires examination of both bone-resorbing osteoclasts and bone-forming osteoblasts.

Osteoclastogenesis and Bone Erosion

Osteoclasts, derived from hematopoietic precursor cells of monocyte lineage, serve as the only cell type capable of resorbing the mineralized bone matrix[25][28]. The differentiation of osteoclast precursor cells into mature multinucleated osteoclasts depends critically on two signals: macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor kappa-B ligand (RANKL)[25][28]. M-CSF binds to the c-Fms receptor on osteoclast precursors, promoting their survival and proliferation, while RANKL binding to RANK triggers the differentiation cascade[25][28].

In PsA, multiple pro-inflammatory cytokines upregulate RANKL expression, including TNF-α, IL-1β, IL-6, and IL-17[25][28]. T cells, particularly Th17 cells, express membrane-bound RANKL and can directly activate osteoclast differentiation[25][28]. The elevated TNF-α present in PsA synovial fluid and tissue amplifies RANKL expression in both fibroblasts and T cells while simultaneously enhancing osteoclast precursor sensitivity to these signals[25][28]. Studies quantifying circulating osteoclast precursor frequencies in PsA patients have revealed dramatically elevated numbers in peripheral blood, with particularly high frequencies in patients with radiographically evident bone erosions[28]. These circulating precursors spontaneously differentiate into osteoclasts without exogenous RANKL or M-CSF stimulation, indicating pre-activation by systemic inflammatory mediators[28]. Intriguingly, peripheral blood mononuclear cells from PsA patients can induce osteoclastogenesis in healthy control cells through production of TNF-α and other soluble mediators[28].

The RANK-RANKL interaction triggers multiple intracellular signaling cascades within osteoclast precursors, particularly activation of the TNF receptor-associated factor 6 (TRAF6) adaptor protein[25][28]. TRAF6 activation drives NF-κB and mitogen-activated protein kinase signaling, leading to calcium-calcineurin signaling and activation of the critical transcription factor nuclear factor of activated T cells, cytoplasmic 1 (NFATc1)[25]. NFATc1 drives expression of genes encoding the osteoclast-specific proteolytic enzymes cathepsin K and tartrate-resistant acid phosphatase as well as the proton pump necessary for the acidic microenvironment required for bone resorption[25].

Osteoprotegerin (OPG), a soluble decoy receptor for RANKL, acts as a physiological brake on osteoclastogenesis[25][28]. Studies of PsA patient synovial fluid demonstrate that treatment with recombinant OPG substantially reduces osteoclast formation from patient mononuclear cells, establishing RANKL as critical for the enhanced osteoclastogenesis observed in PsA[28]. Therapeutic strategies targeting the RANKL pathway through OPG-Fc molecules represent an alternative approach to TNF-α and IL-17/IL-23 inhibition for controlling bone loss in PsA.

Osteoblastogenesis and New Bone Formation

The formation of new bone at entheseal sites and within synovial tissue constitutes a peculiar aspect of PsA pathogenesis not prominently observed in rheumatoid arthritis[29]. Bone morphogenetic proteins (BMPs) and members of the Wnt signaling family play central roles in driving osteoblast differentiation and bone formation[16][29]. The Wnt/β-catenin pathway promotes osteoblast formation by stimulating expression of Runx2, the master transcription factor controlling osteoblast gene expression[16][29]. However, in the inflammatory milieu of PsA, TNF-α-mediated upregulation of DKK-1 and sclerostin antagonizes Wnt signaling and suppresses osteoblastogenesis[16][29], creating local areas of impaired bone formation adjacent to erosion sites.

Conversely, IL-22, produced by Th17 and other T cell subsets, potently promotes osteoblast differentiation through STAT3-dependent signaling[3][4]. IL-22 stimulation of synovial fibroblasts and osteoblast precursors leads to increased expression of bone morphogenetic proteins and upregulation of genes driving mineralized bone matrix synthesis[3][4]. The IL-17A-induced production of IL-22 by specific T cell subsets may explain the localized bone formation observed within PsA synovium and entheseal tissues, where these cells concentrate[3][4]. Additionally, IL-22 suppresses osteoclastogenesis through mechanisms involving GM-CSF production, creating a local environment where bone formation predominates over bone loss[3][4].

The enigmatic simultaneous occurrence of bone erosion and formation in PsA likely reflects spatial segregation of these processes, with IL-17 and TNF-α driving osteoclastogenesis at the pannus-bone interface while IL-22 and bone morphogenetic proteins promote osteoblastogenesis in adjacent synovial tissue[3][4]. Recent work examining the osteoid production by osteoblasts and mineralization processes suggests that IL-17 may actually stimulate osteoblasts to produce RANKL, providing a direct link between the Th17 response and both bone formation and resorption through different mechanisms[16].

The Enthesis: A Special Site of Vulnerability and Inflammation

The enthesis, defined as the anatomical junction where tendons, ligaments, and joint capsules insert into bone, represents a unique anatomical site that bears the brunt of PsA pathology[4][56]. Enthesitis—inflammation at these insertion sites—characterizes the spondyloarthritis family of diseases, to which PsA belongs, and often precedes peripheral joint involvement. The enthesis experiences substantial mechanical stress during normal movements, generating forces that exceed those experienced by synovial joints[4][56]. This biomechanical loading creates microtrauma at entheseal sites, triggering activation of mesenchymal stem cells and local immune responses[4][56].

Recent investigations indicate that patients with PsA possess an altered threshold to mechanical stress, responding to physiological levels of force with pathological inflammation[56]. This differential response likely results from genetic predisposition combined with dysregulated innate immune pathways including increased Toll-like receptor sensitivity[31]. Mechanical loading of mesenchymal stem cells and fibroblasts activates production of CXCL1 and CCL2 chemokines, recruiting monocytes that can differentiate into bone-resorbing osteoclasts[4]. The enthesis becomes infiltrated with innate immune cells including macrophages, mast cells, and neutrophils, which release IL-17 and TNF-α[3][4][56]. IL-17 acts as a major inflammatory mediator at the enthesis, promoting neutrophil infiltration through upregulation of adhesion molecules and production of chemokines[3][56].

The chronic inflammation at entheseal sites in PsA is accompanied by new bone formation, creating characteristic entheseophytes (bony entheseal spurs) and syndesmophytes (ossification of ligamentous insertions) visible on radiographs[56]. IL-22 plays a particularly important role in entheseal new bone formation, acting on mesenchymal stem cells to promote osteoblast differentiation and bone matrix synthesis[3][56]. The presence of IL-17-producing mast cells and T cells at entheseal sites, combined with local IL-23 production, creates an environment conducive to both inflammatory damage and paradoxical new bone formation.

Metabolic Reprogramming and Glycolytic Activation

Recent research has revealed that inflammatory cells in PsA, including keratinocytes and immune cells, undergo metabolic reprogramming characterized by elevated aerobic glycolysis, a process distinct from oxidative phosphorylation despite adequate oxygen availability[48]. This metabolic shift, termed the Warburg effect when observed in cancer cells, provides rapid ATP synthesis supporting the energy demands of proliferating cells and enables synthesis of biosynthetic precursors[48]. In psoriatic lesions and PsA joints, enhanced glycolytic flux has been documented in keratinocytes and dendritic cells, driven by upregulation of glycolytic enzyme expression including hexokinase 2 (HK2), phosphoglycerate mutase 1 (PGAM1), and enolase[48].

The metabolic shift toward glycolysis is regulated by multiple signaling pathways activated in PsA. The Akt/mTOR/HIF-1α (hypoxia-inducible factor-1 alpha) pathway controls glycolytic enzyme expression in activated immune cells and keratinocytes[48]. HIF-1α, stabilized under hypoxic conditions characteristic of inflamed tissues, transcriptionally activates genes encoding glycolytic enzymes and simultaneously suppresses oxidative phosphorylation[48]. In PsA synovium, the combination of increased cellularity, enhanced vascular permeability, and intermittent vascular occlusion creates localized hypoxia that stabilizes HIF-1α and promotes glycolytic metabolism[45].

The functional consequences of this metabolic reprogramming extend beyond merely providing ATP. Glycolytic intermediates feed into biosynthetic pathways including those producing nucleotides, amino acids, and lipids required for rapid cell proliferation and inflammatory mediator synthesis[48]. Activated dendritic cells in PsA require enhanced glycolysis to support the synthesis of IL-23, TNF-α, and other pro-inflammatory cytokines, and pharmacological inhibition of glycolytic enzymes reduces pro-inflammatory cytokine production[45][48]. Furthermore, the metabolic state of T cells influences their differentiation, with enhanced glycolysis promoting Th17 rather than Treg differentiation through effects on mTOR signaling[48].

Epigenetic Modifications and Chromatin Remodeling

Beyond genetic variations affecting protein sequences, heritable changes in DNA methylation and histone modifications drive dysregulated gene expression in PsA. DNA methylation at CpG dinucleotides, catalyzed by DNA methyltransferases, typically correlates with transcriptional repression of affected genes[38][41]. Genome-wide methylation studies comparing psoriatic and normal skin have identified numerous differentially methylated regions affecting genes involved in immune regulation, keratinocyte differentiation, and inflammatory pathways[38][41].

Histone modifications, including acetylation and methylation of specific lysine and arginine residues on histone proteins, profoundly influence chromatin accessibility and transcriptional activity[38][41]. Histone acetylation generally promotes transcription by opening chromatin structure and facilitating transcription factor binding, while certain histone methylation marks (such as H3K9 and H3K27 trimethylation) typically repress transcription[38][41]. In psoriasis and PsA, dysregulation of histone acetyltransferase and histone deacetylase activity leads to altered expression of IL-23, IL-17, and other inflammatory genes[38][41].

TNF-α signaling can directly influence histone modifications through effects on chromatin-modifying enzymes. Research has demonstrated that TNF-α phosphorylation of neural Wiskott-Aldrich syndrome protein (N-WASP) leads to degradation of histone methyltransferases G9a and GLP, reducing repressive H3K9 methylation marks and increasing IL-23 expression[38][41]. This mechanistic link between TNF-α signaling and IL-23 regulation through histone modifications exemplifies the integration of inflammatory signaling with epigenetic control of gene expression.

MicroRNAs, non-coding RNA molecules of approximately twenty-two nucleotides, regulate gene expression post-transcriptionally through base-pairing with mRNA targets, leading to translational repression or mRNA degradation[42]. Dysregulated microRNA expression has been documented in PsA, with several microRNAs showing altered abundance in CD4+ T cells and other immune cells. The miR-146a microRNA, highly expressed in T cells from inflammatory arthritis patients, demonstrates upregulation in response to TNF-α stimulation, suggesting a feedback regulation of TNF-α signaling[42]. Genetic variants in microRNA genes, including the miR-146a rs2910164 polymorphism and miR-155 rs767649 variant, have been associated with PsA susceptibility in case-control studies, though the functional consequences remain incompletely characterized[42].

Angiogenesis and Vascular Dysregulation

The inflamed synovium and psoriatic skin lesions in PsA demonstrate dysregulated angiogenesis characterized by formation of immature, morphologically abnormal blood vessels[33][36]. Histomorphological examination reveals elongated, bushy, torturous vessels in PsA joints, contrasting with the straighter, more orderly vasculature of rheumatoid arthritis[29][33]. These morphological abnormalities reflect an imbalance between angiogenic and anti-angiogenic signals, promoting new vessel formation while compromising vessel maturation and function.

Vascular endothelial growth factor (VEGF), the prototypical angiogenic factor, becomes elevated in PsA serum and synovial fluid, where it stimulates endothelial cell proliferation, migration, and permeability[33][36]. VEGF levels correlate with disease activity measures including the Disease Activity Score, C-reactive protein elevation, and swollen joint counts[36]. Hypoxia-inducible factor-1α (HIF-1α) drives VEGF transcription in response to local tissue hypoxia characteristic of inflamed joints[36]. The inflammatory milieu itself promotes angiogenesis through effects of TNF-α, IL-17, and interleukins on endothelial cells and supporting cells[33][36].

Angiopoietins regulate vascular maturation through effects on the Tie-2 receptor expressed on endothelial cells[33]. Ang-1 promotes vessel maturation and stabilization, while Ang-2 acts antagonistically in the absence of VEGF or agonistically when VEGF is present, promoting vascular sprout formation[33]. The elevated Ang-2 levels observed in PsA synovium, especially following anti-TNF-α therapy, suggest VEGF-dependent promotion of angiogenesis[33]. The concomitant expression of multiple angiogenic molecules creates a permissive environment for pathological vessel formation.

Angiogenesis contributes to PsA pathogenesis through multiple mechanisms beyond merely increasing nutrient delivery. Expanded vasculature increases vascular permeability through effects of VEGF and other permeability factors, facilitating immune cell extravasation into inflamed tissues[33]. Newly formed vessels express enhanced levels of adhesion molecules promoting leukocyte recruitment[33]. Additionally, angiogenesis driven by hypoxia-induced HIF-1α expression creates local metabolic conditions favoring glycolytic metabolism and pro-inflammatory immune responses[45][48].

Complement Activation and Alternative Pathway Dysregulation

The complement system, comprising over thirty plasma and membrane-bound proteins, serves as an essential component of innate immunity and also modulates adaptive immune responses[32]. Activation through three distinct pathways—classical, alternative, and lectin—converges on formation of the membrane attack complex and generation of anaphylatoxins C3a and C5a that promote inflammation and immune cell recruitment[32]. While complement activation is well-established in rheumatoid arthritis, less information exists regarding complement in PsA[32].

Evidence suggests involvement of the complement system in PsA pathogenesis, with some studies demonstrating complement activation in PsA synovial fluid[32]. The contribution of different complement pathways to PsA requires further investigation, though genetic associations with complement-related genes and the therapeutic effectiveness of TNF-α inhibitors (which may partially work through reducing complement activation) suggest a pathogenic role[32]. The alternative pathway of complement, initiated by direct activation of C3 by pathogen-associated molecular patterns or damage-associated molecular patterns, may be particularly relevant in PsA given the proposed role of innate immune dysregulation in this disease[32][35].

Toll-Like Receptors: Pattern Recognition and Innate Immune Activation

Toll-like receptors (TLRs) represent a family of pattern-recognition receptors that detect microbial pathogens and endogenous damage signals, triggering innate immune responses[31][34]. TLR2, which recognizes peptidoglycan from gram-positive bacteria, demonstrates upregulated expression on peripheral blood monocytes of PsA patients compared with healthy controls[31]. This upregulation of TLR2 suggests enhanced responsiveness to gram-positive bacterial components, potentially through streptococcal antigens, which have been proposed as environmental triggers for PsA[31].

TLR ligation on innate immune cells leads to MyD88-dependent signaling activating NF-κB and mitogen-activated protein kinases, culminating in pro-inflammatory cytokine production[31][34]. The upregulation of TLR2 on PsA monocytes may enhance their inflammatory responses to bacterial components, providing a mechanism through which environmental microbial triggers could amplify disease activity[31]. Additionally, TLR4, which recognizes lipopolysaccharide from gram-negative bacteria, shows association with PsA in some studies, suggesting dysregulated responsiveness to multiple bacterial species[34].

Microbiota-Immune Dysregulation Interface

Emerging evidence indicates that dysbiosis—abnormal composition of the microbiota—contributes to PsA pathogenesis through breakdown of immune tolerance to commensal bacteria[24]. The skin microbiota in psoriasis differs substantially from healthy skin, with alterations in bacterial community composition potentially enabling expansion of pro-inflammatory strains[24]. Similarly, the gut microbiota in PsA patients shows evidence of dysbiosis, with reduced diversity and altered representation of specific bacterial taxa[24]. The gut barrier dysfunction frequently accompanying PsA allows bacterial lipopolysaccharides and other microbial antigens to cross into the lamina propria, triggering innate immune activation[24].

The proposed role of molecular mimicry, wherein cross-reactive T cells respond to both streptococcal antigens and host self-antigens, has been investigated as a mechanism linking streptococcal infection to PsA[24]. However, recent studies emphasize that while CD8+ peripheral blood T cells may respond to homologous peptides shared between streptococcal and self-proteins, the critical CD4+ T cells necessary to initiate psoriasis may not be similarly engaged[24]. This suggests that abnormal innate immune responses to bacterial dysbiosis rather than classical molecular mimicry may better explain the microbial connection to PsA pathogenesis[24].

Clinical Phenotypes and Their Mechanistic Basis

Psoriatic arthritis presents with striking heterogeneity in clinical phenotypes, reflecting variable involvement of different joint groups and anatomical sites[20][22][23]. This heterogeneity complicates diagnosis, predicts disease progression, and influences treatment response, underscoring the need for mechanistic understanding of phenotypic variation[20][22][23].

Oligoarticular and Polyarticular Presentations

The asymmetric oligoarticular pattern, affecting four or fewer joints, represents the most common initial presentation, occurring in at least sixty percent of PsA cases at disease onset[20]. However, the majority of oligoarticular patients progress to polyarticular disease over time[20]. Notably, the phenotypic transition from oligoarthritis to polyarthritis correlates with expansion and proliferation of pro-inflammatory T cell populations, particularly elevation of Th17 cells and CD8+ T cells expressing IL-17[20].

Polyarticular arthritis, typically symmetric and involving five or more joints, resembles rheumatoid arthritis superficially but differs pathologically through greater frequency of distal interphalangeal joint involvement and higher propensity for bone proliferation[20]. Mechanistically, polyarticular disease associates with heightened systemic levels of pro-inflammatory cytokines including IL-17, TNF-α, and IL-6 compared with oligoarticular presentations[29]. The expanded inflammatory cell populations in polyarticular PsA may reflect both increased Th17 differentiation and altered regulatory T cell function, though studies directly comparing T cell frequencies between oligoarticular and polyarticular phenotypes remain limited.

Enthesitis and Dactylitis: Distinctive PsA Features

Enthesitis, recognized as a hallmark of PsA and other spondyloarthropathies, may precede joint involvement and independently predicts disease progression[4][56]. The susceptibility of the enthesis to inflammation likely reflects its unique anatomical properties—the concentrated mechanical stresses it experiences during normal movement trigger localized innate immune activation[4][56]. The presence of PsA-specific genetic associations with IL-23/IL-17 pathway components combined with mechanical stress-induced mesenchymal cell activation creates the milieu promoting entheseal inflammation[4][56].

Dactylitis—swelling of entire fingers or toes creating a "sausage digit" appearance—occurs in up to forty percent of PsA patients and associates with severe synovial inflammation extending across tendon sheaths and synovial membranes[3][4]. Histopathological examination of dactylitic digits reveals tenosynovitis (inflammation of the tendon sheath), microenthesitis at tendon insertion sites, and extensive synovial infiltration[3][4]. The pathogenesis involves T cell infiltration into affected tissues with production of IL-17 and TNF-α, promoting neutrophil recruitment and activation of fibroblasts producing matrix-degrading enzymes[3][4].

Axial Involvement and Spondylitis

Axial involvement in PsA manifests as sacroiliitis and spondylitis, occurring in approximately forty-three percent of patients, often coexisting with peripheral joint disease[20][23]. PsA-associated axial disease differs from ankylosing spondylitis through less frequent HLA-B*27 positivity (twenty percent vs. eighty-ninety percent), higher female prevalence, older age at onset, and asymmetric radiographic findings[20]. The syndesmophytes bridging vertebral bodies in PsA are characteristically bulky, asymmetric, and discontinuous, skipping vertebral levels, in contrast to the marginal, symmetric syndesmophytes of ankylosing spondylitis[20].

The mechanisms underlying axial involvement likely parallel those of peripheral PsA, with IL-23/IL-17 axis activation at entheseal and ligamentous insertions promoting bone formation coupled with inflammatory destruction[3][4]. The IL-22 cytokine may play a particularly important role in axial new bone formation, given its potent effects on osteoblast differentiation[3][4].

Therapeutic Implications and Future Directions

The mechanistic understanding of PsA pathogenesis has directly informed development of targeted therapeutics demonstrating clinical efficacy[1][3][4][6]. TNF-α inhibitors, including monoclonal antibodies (infliximab, adalimumab) and soluble receptor fusion proteins (etanercept), remain first-line therapies for moderate-to-severe PsA, with approximately fifty to seventy percent of patients achieving low disease activity with these agents[6]. However, approximately thirty to forty percent demonstrate inadequate initial response or loss of response over time.

IL-17 inhibitors, including monoclonal antibodies against IL-17A (secukinumab, ixekizumab), demonstrate superiority to TNF-α inhibitors in some efficacy measures, particularly for skin disease, though polyarticular joint response rates remain comparable[6]. IL-23 inhibitors (guselkumab, tildrakizumab, risankizumab) represent emerging therapeutic options targeting the upstream cytokine driving Th17 differentiation, with early clinical trials demonstrating efficacy in both skin and joint manifestations[6].

JAK inhibitors (tofacitinib, baricitinib, upadacitinib), which block multiple cytokine signaling pathways simultaneously, offer an oral therapeutic option with efficacy approaching or potentially exceeding conventional biologic therapies for some patients[1][6]. The breadth of cytokine pathways affected by JAK inhibition—including IL-6, IL-23, IL-22, and interferons—may explain their effectiveness in treatment-resistant populations.

The discovery of immunoproteasome pathway involvement in treatment-resistant PsA suggests that selective immunoproteasome inhibitors may benefit patients failing conventional therapies[2][15]. Functional validation studies confirm that immunoproteasome inhibition reduces myeloid-driven inflammation in model systems, supporting clinical investigation of this approach[2][15].

Emerging recognition of the CD8+ T cell contribution to PsA pathogenesis raises the possibility that therapeutics targeting CD8+ T cell responses or promoting CD8+ regulatory T cell generation could prove beneficial. Additionally, the identification of distinct fibroblast subsets with either inflammatory or resolution-promoting phenotypes suggests that therapeutic approaches encouraging fibroblast phenotype switching might prevent permanent joint damage.

The heterogeneity of PsA pathophysiology and variable treatment responses have prompted investigation into predictive biomarkers enabling personalized therapeutic selection. Studies demonstrate that baseline T cell phenotype composition—specifically the relative abundance of Th1 versus Th17 cells—predicts response to specific therapeutic approaches, with TNF-α inhibitors benefiting patients with enriched Th1/Th17 populations while IL-17 inhibitors may be superior for other subsets[6]. This concept of precision medicine in PsA, guided by mechanistic biomarkers, represents a promising future direction.

Conclusion

The pathophysiology of psoriatic arthritis emerges from the integration of genetic predisposition, environmental triggers, and dysregulated immune responses targeting multiple anatomical sites including skin, synovium, enthesis, and bone. The IL-23/IL-17 cytokine axis represents the dominant inflammatory pathway, operating within a complex inflammatory milieu that includes TNF-α, IL-6, and numerous chemokines and growth factors. Multiple innate immune cell populations—macrophages, dendritic cells, neutrophils, and mast cells—serve as primary drivers of inflammation, creating a permissive environment for Th17 and CD8+ T cell responses. Paradoxically, the same inflammatory mediators that drive synovial inflammation and cartilage destruction simultaneously promote new bone formation at entheseal sites, creating the distinctive radiographic pattern of PsA with simultaneous erosions and proliferation[1][3][4][5][6]. Synovial fibroblasts, activated by IL-17 and TNF-α, undergo phenotypic transformation from structural cells to invasive effector cells producing matrix-degrading enzymes and pro-inflammatory mediators. Metabolic reprogramming toward enhanced glycolysis supports the inflammatory responses while epigenetic modifications ensure sustained dysregulation of key inflammatory genes. The mechanistic insights gained from recent molecular and cellular investigations have directly enabled development of effective targeted therapies, with JAK inhibitors, IL-17 inhibitors, and IL-23 inhibitors demonstrating efficacy in controlling disease activity. Future directions include refinement of mechanistic biomarkers to guide precision medicine approaches, investigation of previously underappreciated pathways such as immunoproteasome-mediated antigen presentation in treatment-resistant disease, and exploration of therapies promoting resolution of inflammation through fibroblast phenotype switching and regulatory T cell expansion. The remarkable clinical heterogeneity of PsA reflects variable involvement of these mechanistic pathways across affected individuals, emphasizing the need for continued integration of molecular understanding with clinical phenotyping to achieve optimal patient outcomes.